<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972841</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-101</org_study_id>
    <secondary_id>2012-005735-91</secondary_id>
    <secondary_id>U1111-1153-9095</secondary_id>
    <nct_id>NCT01972841</nct_id>
  </id_info>
  <brief_title>This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder</brief_title>
  <acronym>SYNERGY</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to examine how well two medicines (solifenacin succinate and
      mirabegron) combined work compared to each medicine alone in the treatment of bladder
      problems.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">October 22, 2015</completion_date>
  <primary_completion_date type="Actual">October 22, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>A micturition was defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in Mean Volume Voided Per Micturition</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The number of incontinence episodes was calculated as the total number of incontinence episodes on valid diary days recorded during the 7-day micturition diary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in Corrected Micturition Frequency</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the number of times a participant recorded an urgency incontinence episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The mean number of urgency incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>An urgency episode was a complaint of a sudden, compelling desire to pass urine, which was difficult to defer; it was recorded when a micturition or incontinence episode was recorded and the severity of urinary urgency recorded was 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant went to bed with the intention to sleep until the time the patients got up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes</measure>
    <time_frame>Baseline and weeks 4, 8, 12, and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The mean number of nocturia episodes per 24hr was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pads Used at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8 and 12 (up to 12 weeks)</time_frame>
    <description>The number of pads used was the number of times a participant recorded a new pad used on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EOT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours</measure>
    <time_frame>Baseline and weeks 4, 8 and 12 (up to 12 weeks)</time_frame>
    <description>The mean number of pads used per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8,12 and EoT (up to 12 weeks)</time_frame>
    <description>The number of days with &lt; 8 micturitions was the number of valid diary days during the 7-day micturition diary period with less than 8 micturitions per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence-Free Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The number of incontinence-free days with &lt; 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with &lt; 8 micturitions per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)</measure>
    <time_frame>Baseline and weeks 4, 8, 12, EoT (up to 12 weeks)</time_frame>
    <description>The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
    <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion in the OAB-q (seen in this outcome measure) consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion in the OAB-q (seen in this outcome measure) consisted of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total HRQoL score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The Coping score was calculated by adding 8 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The Concern score was calculated by adding 7 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The Sleep score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The Social score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT</measure>
    <time_frame>Week 12 and EoT (up to 12 weeks)</time_frame>
    <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIC Scale: Impression in General Health at Week 12 and EoT</measure>
    <time_frame>Week 12 and EoT (up to 12 weeks)</time_frame>
    <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression</measure>
    <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
    <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed</measure>
    <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
    <description>The WPAI:SHP was a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes were expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working</measure>
    <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment</measure>
    <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment</measure>
    <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8 and 12 in TS-VAS</measure>
    <time_frame>Baseline and week 4, 8 and 12</time_frame>
    <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with ≥ 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8 , 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with micturition frequency normalization was defined as any participant who had ≥ 8 micturitions/24 hours at baseline and &lt; 8 micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants with a major (≥ 2 points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</measure>
    <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the HRQL total score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)</time_frame>
    <description>A TEAE refered to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume</measure>
    <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
    <description>PVR volume was assessed by ultrasonography or a bladder scanner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference</measure>
    <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
    <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">3527</enrollment>
  <condition>Urinary Bladder Overactive</condition>
  <condition>Urinary Bladder Diseases\Urologic Diseases</condition>
  <condition>Overactive Bladder</condition>
  <condition>Urgency Incontinence</condition>
  <arm_group>
    <arm_group_label>1: Solifenacin 5 mg + Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Solifenacin 5 mg + Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received matching placebo once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Solifenacin 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5:Mirabegron 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: Mirabegron 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>1: Solifenacin 5 mg + Mirabegron 25 mg</arm_group_label>
    <arm_group_label>2: Solifenacin 5 mg + Mirabegron 50 mg</arm_group_label>
    <arm_group_label>4: Solifenacin 5 mg</arm_group_label>
    <other_name>Vesikur</other_name>
    <other_name>Vesitrim</other_name>
    <other_name>YM905</other_name>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>1: Solifenacin 5 mg + Mirabegron 25 mg</arm_group_label>
    <arm_group_label>2: Solifenacin 5 mg + Mirabegron 50 mg</arm_group_label>
    <arm_group_label>5:Mirabegron 25 mg</arm_group_label>
    <arm_group_label>6: Mirabegron 50 mg</arm_group_label>
    <other_name>YM178</other_name>
    <other_name>Betmiga</other_name>
    <other_name>Betanis</other_name>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match solifenacin succinate</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_label>5:Mirabegron 25 mg</arm_group_label>
    <arm_group_label>6: Mirabegron 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match mirabegron</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>1: Solifenacin 5 mg + Mirabegron 25 mg</arm_group_label>
    <arm_group_label>2: Solifenacin 5 mg + Mirabegron 50 mg</arm_group_label>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_label>4: Solifenacin 5 mg</arm_group_label>
    <arm_group_label>5:Mirabegron 25 mg</arm_group_label>
    <arm_group_label>6: Mirabegron 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was willing and able to complete the micturition diary and questionnaires
             correctly and able to measure his/her vital signs at home at stipulated time points,
             using the device provided by the study personnel, and to adequately record the
             readings;

          -  Subject had symptoms of &quot;wet&quot; OAB (urinary frequency and urgency with incontinence)
             for at least 3 months;

        Exclusion Criteria:

          -  Subject had significant PVR volume (&gt; 150 mL);

          -  Subject had a neurological cause for detrusor overactivity (e.g. neurogenic bladder,
             diabetic neuropathy with autonomic component or bladder involvement, or systemic or
             central neurological disease such as multiple sclerosis and Parkinson's disease with
             autonomic component or bladder involvement). An autonomic component could be inferred
             when autonomic functions were affected, including heart rate, blood pressure,
             perspiration and digestion.

          -  Subject had an indwelling catheter or practices intermittent self catheterization.

          -  Subject had chronic inflammation such as bladder pain syndrome /interstitial cystitis,
             symptomatic bladder stones or any previous or current radiation cystitis.

          -  Subject had received intravesical treatment in the past 12 months with e.g., botulinum
             toxin, resiniferatoxin, capsaicin.

          -  Subject had moderate to severe hepatic impairment

          -  Subject had severe renal impairment

          -  Subject had a clinically significant abnormal ECG

          -  Subject had a concurrent malignancy or history of cancer (except noninvasive skin
             cancer) within the last 5 years prior to screening.

          -  Subject had an average QTcF interval &gt; 450 ms for males or &gt; 470 ms for females based
             on the triplicate ECGs completed at Screening or is at risk of QT prolongation (e.g.,
             family history of long QT syndrome, hypokalaemia).

          -  Subject had severe hypertension, which is defined as a sitting average systolic blood
             pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10049 Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10112 TFI, LLC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10104 Clinical Research Advantage, Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10021 Beach Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10122 Orange County Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10098 Skyline Research</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10539 Citrus Valley Medical Research</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10082 American Clinical Trials</name>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <zip>90716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10132 Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10133 Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10536 Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>93404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10149 Bayview Research Group</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10559 UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10003 San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10545 San Diego Institute for Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10106 West Coast Clinical Research</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10595 Bayview Research Group</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10034 Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10070 Physicians' Research Options/Red Rocks OB/GYN</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10053 Western Clinical Research, Inc.</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10128 Clinical Research Center of CT</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10018 Grove Hill Clinical Research</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10170 Yale - New Haven Hospital West Haven VAMC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10123 Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10060 Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10097 A.G.A. Clinical Trials DBA Neostart Group</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10148 Best Quality Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10153 Palmetto Professional Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10159 Urological Research Network</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10534 South Florida Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10535 South Florida Medical Research</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10165 East Coast Institute for Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10091 Health Awareness</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10150 Suncoast Clinical Research, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10158 Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10124 Winter Park Urology Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10134 Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10009 South Broward Research</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10540 Demaur Clinical Research, INC</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10554 Private Practice</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10095 Florida Urology Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10010 Southeastern Research Group, Inc</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10014 Private Practice</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10037 Atlanta Medical Research Institute</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10127 Perimeter North Medical Research, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10120 WR-Mount Vernon Clinical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10024 GTC Research</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10078 Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10088 Centex Studies, Inc.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10074 Medpharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10025 Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10558 Chesapeake Urology Research Associates</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10560 Chesapeake Urology Research Associates</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10282 Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10114 Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10152 Female Pelvic Medicine &amp; Urogynecology Institute</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10542 Adult &amp; Pediatric Urology Group</name>
      <address>
        <city>Sartell</city>
        <state>Minnesota</state>
        <zip>56377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10110 Montana Health Research Institute, Inc.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10154 Montana Medical Research Inc</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10553 Women's Clinic of Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10140 IVCTLV</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10002 Urology Center Research Institute</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10051 AdvancedMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10047 Lawrence OBGYN Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>86480</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10162 Phoenix OB-GYN Associates, LLC</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10011 Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10015 Urology Group of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10077 Northeast Urogynecology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10089 Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10026 AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10040 Premier Medical Group Of The Hudson Valley</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10073 Manhattan Medical Research Practice, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10249 New York Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10168 Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10126 Premier Medical Group</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <zip>12550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10028 Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10593 Upstate Clinical Research Associates LLC</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10076 Carolina Clinical Trials</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10129 PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10549 Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10062 Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10050 Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10033 Ohio Clinical Research</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10067 Family Practice Center of Wadsworth</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10551 The Christ Hospital</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10109 Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10541 Sunstone Medical Research</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10008 Urologic Consultants of Southeastern Pennsylvania</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10045 Lancaster Urology</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10017 Philadelphia Clinical Research, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10167 University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10250 Preferred Primary Care Physicians Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10248 Preferred Primary Care Physicians, Inc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10063 Preferred Primary Care Physician Research</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10012 Advanced Clinical Concepts</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10166 Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10094 University Medical Group</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10046 Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10079 PMG Research of Charleston, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10117 Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10023 Hillcrest Clinical Research, LLC</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10101 Palmetto Clinical Research</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10006 Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10084 Dynamed Clinical Research of Austin,LLC dba DM Clinical Resc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10066 Texas Urology PA</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10065 Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10085 Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10108 Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10219 Methodist Urology Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10093 Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10090 Protenium Clinical Research, LLC</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10105 Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10111 Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10092 Physicians' Research Options/Salt Lake Women's Center</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10032 National Clinical Research Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10064 The Group for Women</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10083 Urology of Virginia, PLLC.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10013 Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10004 Integrity Medical Research, LLC</name>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10155 Seattle Women's Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10135 Walla Walla Clinic</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AR54005 IUBA - Instituto Urologico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1419</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AR54003 Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AR54006 Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AR54001 CDU - Centro de Urología</name>
      <address>
        <city>Ciudad Autónoma Buenos Aires</city>
        <zip>C1120AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AR54004 Instituto de Investigaciones Clnicas Rosario</name>
      <address>
        <city>Rosario Provincia De Santa Fe</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61026 Ballarat Urology</name>
      <address>
        <city>Ballarat</city>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61022 Brisbane South Clinical Research Centre</name>
      <address>
        <city>Brisbane</city>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61005 Hunter Clinical Research</name>
      <address>
        <city>Broadmeadow</city>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61015 Repatriation General Hospital</name>
      <address>
        <city>Daw Park</city>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61025 Western Health</name>
      <address>
        <city>Footscray</city>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61012 Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61010 Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61002 The Royal Womens Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61004 Keogh Institute for Medical Research</name>
      <address>
        <city>Perth</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61007 Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61008 Epworth Healthcare</name>
      <address>
        <city>Richmond</city>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61019 AusTrialsSherwood</name>
      <address>
        <city>Sherwood</city>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61017 Healthpac Medical Centre</name>
      <address>
        <city>Sydney</city>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61021 Royal Hospital for Women</name>
      <address>
        <city>Sydney</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site AU61011 Illawarra Health and Medical Research Institute</name>
      <address>
        <city>Wollongong</city>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32004 Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32011 Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32014 Hart Ziekenhuis</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32012 Sint-Trudo Ziekenhuis, Campus Sint Jozef/Sint-Anna</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35904 University Hospital (UMHAT) - George Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35908 MHAT Plovdiv AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35902 MHAT Ruse</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35905 MHAT Alexandrovska Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35903 MHATEM Pirogov</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35906 UMHAT Varna</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35910 MHAT</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15029 Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15035 Glenrose Rehabilitation Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15033 Prohealth</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15008 Private Practice</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 3J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15001 The Male/Female Health &amp; Research Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15006 Bramalea Medical Centre</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 4S5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15003 Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15042 G. Kenneth Jansz Medicine Professional Corporation</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15044 McMaster Institute of Urology</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15031 Centre for Applied Urology Research (CAUR)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15007 Eunoia2 Incorporated</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2N 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15034 Oxford/Richmond Medical</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15032 Stanley Flax Medical Prof Corp</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15013 Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15004 Primehealth Clinical Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15002 Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15026 Rhodin Recherche Clinique</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15015 Recherches Cliniques Theradev, Inc.</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15021 Urology South Shore Research</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15030 UroLaval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G 2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15040 RechercheGCP Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2R1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15020 Diex Research Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 3C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15010 Ultra Med Research, Inc.</name>
      <address>
        <city>Point-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15027 Diex Research Sherbrooke Inc</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15039 Pro-recherche</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15025 Clinique RSF Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86017 Affiliated Union Hospital of Fujian Medical Uni.</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86025 Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86009 Peking University 3rd Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86013 Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86014 The First Hospital Bethune of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86002 Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86028 General Hospital of Chengdu Military Region of PLA</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86029 Southwest Hospital (Chongqing)</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86016 Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86027 Second Hospital of Lanzhou University</name>
      <address>
        <city>Lan Zhou</city>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86030 Lanzhou University First Hospital</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86020 The First Affiliated Hospital of NanChang Univers</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86023 Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86021 HuaDong Hosipital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86003 Shanghai Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86012 The Fifth People's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86011 The Second Affiliated Hospital of Soochow Universi</name>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86010 1st Affiliated Hosptital of Suchow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86026 The First Affiliated Hospital of Wenzhou Medical C</name>
      <address>
        <city>Wenzhou</city>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86022 Tongji Hospital, Tongji Medical College of Hust</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86015 Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN86018 Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CO57003 Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CO57004 Instituto de Coloproctologia ICO SAS</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42015 Centrum ambulantni gynekologie a primarni pece</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42003 SANUS</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42001 Fakultni Nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42002 Hospital Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42011 Hospital Novy Jicin</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42010 G-centrum Olomouc S.R.O.</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42014 Private Practice</name>
      <address>
        <city>Ostrava</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42005 Research Site s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42007 Uro-Santé/Nová Brumlovka</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42013 Urology Clinic</name>
      <address>
        <city>Sternberk</city>
        <zip>78501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42009 Hospital Uherské Hradiště a.s.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42006 Private Practice</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45012 Aalborg Sygehus Nord</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45013 University Hospital of Aarhus, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site EE37201 Parnu Hospital</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site EE37205 West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site EE37202 Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FI35801 Kouvolan Lääkäriasema</name>
      <address>
        <city>Kouvola</city>
        <zip>45200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FI35803 Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FI35802 Meilahti Hospital</name>
      <address>
        <city>Vantaa</city>
        <zip>01400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33007 Centre Hospitalier Louis Pasteur</name>
      <address>
        <city>Colmar Cedex</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33010 CHU Hopital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33008 CHU Nantes</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33002 CHU Carémeau</name>
      <address>
        <city>Nimes Cedex</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33001 Hopital Tenon</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33024 Hopital Tenon</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33013 Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33011 Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33012 Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33005 Hopital Bretonneau</name>
      <address>
        <city>Tours Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49008 Private Practice</name>
      <address>
        <city>Bad Ems</city>
        <zip>56130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49031 Urologisches Zentrum Refrath</name>
      <address>
        <city>Bergisch Gladbach</city>
        <zip>51427</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49033 Universitsy Clinic Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002 Private Practice</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49032 Urologicum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49010 Private Practice</name>
      <address>
        <city>Ganderkesee</city>
        <zip>27777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49011 Private Practice</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06132</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49013 Private Practice</name>
      <address>
        <city>Leipzig</city>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49003 Private Practice</name>
      <address>
        <city>Lutherstadt Eisleben</city>
        <zip>6295</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49034 LMU Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001 Private Practice</name>
      <address>
        <city>Neustadt I. Sachsen</city>
        <zip>1844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49026 Zentrum fuer Onkologie und Urologie Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49014 Private Practice</name>
      <address>
        <city>Sangerhausen</city>
        <zip>6526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GR30009 Aretaieio/Maginio</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HK85204 The Chinese Uni of HK, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HK85201 Kwong Wah Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HK85203 The Chinese Uni of HK, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <zip>30-32</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36003 Dr.Szarka Ödön Kistérségi Egészségügyi Szolgáltató Kft</name>
      <address>
        <city>Csongrád</city>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36007 Mediroyal Prevention Center</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36005 Uro-clin Ltd</name>
      <address>
        <city>Pecs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36013 Sopron Erzsébet Hospital</name>
      <address>
        <city>Sopron</city>
        <zip>H-9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36001 Donatella 99BT</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36012 Veszprém County Cholnoky Ferenc Hospital</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39022 Azienda Ospedale Umberto I (Ancona)</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39007 Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39001 U.O. Dip. di Neuro-Urologia; Univ. di Roma La Sapienza</name>
      <address>
        <city>Latina</city>
        <zip>4100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39020 Ospedale San Raffaele IRCCS, U.O. di Ginecologia e Ostetricia, Unità Funzionale di Uroginecologia</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39003 Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82014 Soon Chun Hyang University Hospital</name>
      <address>
        <city>Bucheon-Si</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82006 Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82016 Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82024 Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82032 Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-421</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82005 Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82029 Daegu Catholic Univ. Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82019 Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82011 Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82031 Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82009 Wonkwang University Hospital</name>
      <address>
        <city>Iksan -Si</city>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82023 Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>405760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82010 Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82025 Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82021 Cheil General Hospital &amp; Women's Healthcare Center</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82020 Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82030 Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82013 Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82017 Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>134-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82002 Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82008 Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82015 Korea University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>136-075</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82001 Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82003 Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82012 Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82004 Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LV37102 Private Practice</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LV37103 Health Centre &quot;Olaine&quot;</name>
      <address>
        <city>Olaine</city>
        <zip>LV-2114</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LV37105 P.Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37008 Kaunas 2nd Clinical Hospital</name>
      <address>
        <city>Kaunas</city>
        <zip>47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37004 KHospital of Lithuanian University of Health Science</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37011 Saules Family Medicine Centre</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37012 Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37005 Public Institution Vilnius City University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37010 Public Institution Vilnius City University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37003 Family Medical Centre Seimos gydytojas</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-01118</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37007 Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site LT37009 Clinics Privatus gydytojas</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60006 Hospital Pulau Pinang</name>
      <address>
        <city>Georgetown</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60001 Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60004 University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60005 Universiti Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60003 Hospital Ummum Sarawak</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY60002 Sime Darby Medical Centre</name>
      <address>
        <city>Petaling Jaya</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX52004 Consultorio de Especialidad en Urologia</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX52001 Centro de Investigacin Basica y Clnica</name>
      <address>
        <city>Guadalajara</city>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX52003 Clinstile, Sociedad Anonima de Capital Variable</name>
      <address>
        <city>Mexico City</city>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX52002 Accelerium Clinical Research/ Hospital San Jorge</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NL31002 Academic Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NL31006 Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NL31005 Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NL31010 Antonius Ziekenhuis Sneek</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NL31001 University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64004 John A Tuckey Ltd Ascot Central</name>
      <address>
        <city>Auckland</city>
        <zip>1541</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64001 Canterbury Urology Research Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8014</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64005 Waikato Urology Research Limited</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64002 Roundhay Medical Centre</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64003 Tauranga Urology Research Ltd</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NZ64006 Cardinal Point Specialist Centre</name>
      <address>
        <city>Whangarei</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NO47006 M3 Helse AS</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NO47008 Norsk Helseklinikk (Heiaklinikken)</name>
      <address>
        <city>Lierskogen</city>
        <zip>3420</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NO47007 Medi3 Clinic AS, Ålesund</name>
      <address>
        <city>Ålesund</city>
        <zip>6003</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51006 Hospital Nacional Guillermo Almenara Irigoyen EsSalud</name>
      <address>
        <city>La Victoria</city>
        <state>Lima</state>
        <zip>13</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51007 Clínica Anglo Americana</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51001 Instituto de Ginecologia y Reproduccion</name>
      <address>
        <city>Lima</city>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51002 Clinica San Borja</name>
      <address>
        <city>Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51004 Clinica San Pablo</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PE51005 Hospital Nacional Hipolito Unanue</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63008 Dr. Pablo O. Torre Memorial Hospital</name>
      <address>
        <city>Bacolod City</city>
        <zip>6100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63005 Davao Doctor's Hospital</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63010 Davao Doctor's Hospital</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63003 University of Santo Tomas Hospital (USTH)</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63009 Chinese General Hospital and Medical Center</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH63004 East Avenue Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48018 Gastromed</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48013 Urovita Ltd.</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48014 Synexus Polska</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48004 NZOZ Szpital Sw.Rodziny Centrum Medyczne</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48010 Nzoz Novita</name>
      <address>
        <city>Lublin</city>
        <zip>20-632</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48011 Nzoz Centrum Urologiczne sp. z o.o.</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48016 Prywatny Gabinet Urologiczny</name>
      <address>
        <city>Opole</city>
        <zip>45-086</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48005 HEUREKA Hanna Szalecka</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48012 Military Institute of Medicine</name>
      <address>
        <city>Warsaw</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48003 CSKMSW</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001 Specjalistyczny Gabinet Lekarski</name>
      <address>
        <city>Warszawa</city>
        <zip>02-929</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48019 Synexus Polska sp. z o. o.</name>
      <address>
        <city>Wrocław</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40015 Spitaul Clinic Judetean de Urgenta Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40004 Spitalul Clinic de Urgenta Sfantul Ioan</name>
      <address>
        <city>Bucuresti</city>
        <zip>42122</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40001 Spiatlul Clinic Th. Burghele</name>
      <address>
        <city>Bucuresti</city>
        <zip>50659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40005 Spiatlul Clinic Th. Burghele</name>
      <address>
        <city>Bucuresti</city>
        <zip>50659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40014 E-URO Cabinet</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400046</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40007 Spital Clinic</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40010 Spitalul Clinic Judetan de Urgenta Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40002 Spitalul Clinic Judetean de Urgenta Timisoara</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70015 LLC Clinical Research Medical Complex</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70023 Penza Regional Clinical Hospatal n. a. N.N. Burdenko</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70019 City Multidisciplinary Hospital No. 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70002 Pavlov St. Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70022 St. Petersburg State Public Health Institution</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70014 OOO Hospital Orkli</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70018 Bashkirsky State Medical University of Roszdrav</name>
      <address>
        <city>Ufa</city>
        <zip>450096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG65001 National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG65002 Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG65003 KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42105 Ruzinovska poliklinika a.s.</name>
      <address>
        <city>Bratislava</city>
        <zip>82101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42107 Zeleznicne zdravotnictvo Kosice, s.r.o.</name>
      <address>
        <city>Kosice</city>
        <zip>4001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42101 Andrologicka a Urologicka Ambulancia</name>
      <address>
        <city>Kosice</city>
        <zip>4013</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42103 UroExam s.r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42108 BrenCare, s. r. o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42104 Urology Outpatient Department</name>
      <address>
        <city>Presov</city>
        <zip>8001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42106 Private Urological Care Center</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42102 CeGys, s.r.o.</name>
      <address>
        <city>Trencin</city>
        <zip>91101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SI38604 General Hospital Murska Sobota</name>
      <address>
        <city>Murska Sobota</city>
        <zip>9000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SI38602 General Hospital Novo Mesto</name>
      <address>
        <city>Novo Mesto</city>
        <zip>8000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27005 Grootte Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27001 Private Practice</name>
      <address>
        <city>Centurion</city>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27006 Parklands Hospital</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27013 Synexus Clinical Research SA (Pty) Ltd</name>
      <address>
        <city>Meyerspark</city>
        <zip>184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27007 Paarl Medical Centre</name>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ZA27002 Mayo Clinic</name>
      <address>
        <city>Roodepoort</city>
        <zip>1709</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34010 Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34024 Hospital San Juan de Dios</name>
      <address>
        <city>Esplugues De Llobregat-Barcelo</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34001 Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe (Madrid)</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34006 Hospital San Rafael</name>
      <address>
        <city>Madrid</city>
        <zip>28016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34004 Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34015 Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28044</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34005 Hospital de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34003 Hospital Universitario Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34007 Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34002 H. U. Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46007 Ladulaas Clinical Studies</name>
      <address>
        <city>Boras</city>
        <zip>506 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46025 Pharmasite</name>
      <address>
        <city>Helsingborg</city>
        <zip>252 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46005 Center för Läkemedelsstudier</name>
      <address>
        <city>Malmö</city>
        <zip>211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46016 Citydiabetes - Stockholm</name>
      <address>
        <city>Stockholm</city>
        <zip>111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46008 Bragée Medect AB</name>
      <address>
        <city>Stockholm</city>
        <zip>115 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46012 Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46003 Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46009 Encia AB, Uppsala Hälsomottagning</name>
      <address>
        <city>Uppsala</city>
        <zip>753 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46017 S3 Clinical Research Centers</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88605 Taichung Veteran General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88611 Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88612 Chi Mei Medical Center, Yong Kang</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88614 Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66002 Chulalongkorn Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66008 Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66005 Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66010 Maharaj Nakorm Chiangmai Hosp</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66006 Songklanagarind Hospital, Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66009 Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66007 Thammasat University Hospital</name>
      <address>
        <city>Pathum Thani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66011 Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR90019 Ankara University Medical Faculty Ibni Sina Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR90013 Uludag University Faculty of Medicine</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR90001 Pamukkale University Faculty of Medicine</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR90017 Bilim University Sisli Florence Nightingale Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34381</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38002 City Hospital No 2</name>
      <address>
        <city>Chernigov</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38015 Regional Municipal Institution, Urology Department</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38013 Dnipropetrovsk State Medical Academy, Mechnikov Dnipropetrov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38006 Shapoval Regional Clinical Centre of Urology and Nephrology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38007 Central Outpatient Hospital of Deanyanskyy Distric</name>
      <address>
        <city>Kiev</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38003 Urology Dpt of Kyiv City Clinical Hospital #3</name>
      <address>
        <city>Kyiv</city>
        <zip>02660</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38010 Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38014 Uzhgorod City Polyclinic</name>
      <address>
        <city>Uzhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38004 Vinnitsa Endocrinology Dispens</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site UA38008 Medical Academy of Postgraduate Education, Urology Clinic</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44009 Sheepcot Medical Centre</name>
      <address>
        <city>Garston</city>
        <state>Watfort</state>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44003 Leighton Hospital</name>
      <address>
        <city>Crewe</city>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44021 Medway Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5WY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44005 North West London Hosp Menopause Clinic</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44024 St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 9TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44025 Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44006 Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44022 The Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44001 Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=254</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <results_first_submitted>May 9, 2018</results_first_submitted>
  <results_first_submitted_qc>May 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <disposition_first_submitted>October 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 24, 2016</disposition_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination Therapy</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urgency</keyword>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Nocturia</keyword>
  <keyword>Solifenacin Succinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who had symptoms of “wet” overactive bladder (OAB) (urgency, urinary frequency and urgency incontinence) for ≥ 3 months were enrolled at 435 centers in 42 countries. Eligible participants went into a single-blind, 4-week placebo run-in period and completed a micturition diary the last 7 days prior to each study visit.</recruitment_details>
      <pre_assignment_details>A total of 6991 participants were screened, 6275 participants received placebo run-in treatment and 3527 participants were randomized into 1 of 6 treatment arms in a 1:1:1:1:2:2 ratio in the 12-week double-blind treatment period. A total of 953 participants were also enrolled in an ambulatory blood pressure monitoring (ABPM) substudy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants who received matching placebo once a day for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Mirabegron 25 mg</title>
          <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Mirabegron 50 mg</title>
          <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Solifenacin 5 mg</title>
          <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="437"/>
                <participants group_id="P4" count="434"/>
                <participants group_id="P5" count="885"/>
                <participants group_id="P6" count="883"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="397"/>
                <participants group_id="P3" count="387"/>
                <participants group_id="P4" count="397"/>
                <participants group_id="P5" count="802"/>
                <participants group_id="P6" count="798"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="83"/>
                <participants group_id="P6" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Never Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by participants</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not have end of treatment page</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized analysis set (RAS), comprised all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants who received matching placebo once a day for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Mirabegron 25 mg</title>
          <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Mirabegron 50 mg</title>
          <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Solifenacin 5 mg</title>
          <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="447"/>
            <count group_id="B2" value="441"/>
            <count group_id="B3" value="437"/>
            <count group_id="B4" value="434"/>
            <count group_id="B5" value="885"/>
            <count group_id="B6" value="883"/>
            <count group_id="B7" value="3527"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="447"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="434"/>
                    <count group_id="B5" value="885"/>
                    <count group_id="B6" value="883"/>
                    <count group_id="B7" value="3527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.46" spread="13.2"/>
                    <measurement group_id="B2" value="56.77" spread="13.46"/>
                    <measurement group_id="B3" value="56.69" spread="13.28"/>
                    <measurement group_id="B4" value="57.88" spread="12.92"/>
                    <measurement group_id="B5" value="56.94" spread="13.78"/>
                    <measurement group_id="B6" value="57.3" spread="13.46"/>
                    <measurement group_id="B7" value="57.16" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="447"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="434"/>
                    <count group_id="B5" value="885"/>
                    <count group_id="B6" value="883"/>
                    <count group_id="B7" value="3527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="338"/>
                    <measurement group_id="B4" value="342"/>
                    <measurement group_id="B5" value="686"/>
                    <measurement group_id="B6" value="684"/>
                    <measurement group_id="B7" value="2738"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="199"/>
                    <measurement group_id="B6" value="199"/>
                    <measurement group_id="B7" value="789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of incontinence episodes/24 h</title>
          <description>An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
          <population>Full analysis set (FAS) comprised all RAS patients who took ≥ 1 dose of double-blind treatment after randomization, reported ≥ 1 micturition in the baseline diary and ≥ 1 micturition postbaseline, reported ≥ 1 incontinence episode in the baseline diary and excluded participants from one site. Participants with available data were included.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="418"/>
                    <count group_id="B2" value="409"/>
                    <count group_id="B3" value="411"/>
                    <count group_id="B4" value="415"/>
                    <count group_id="B5" value="827"/>
                    <count group_id="B6" value="826"/>
                    <count group_id="B7" value="3306"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.41" spread="3.37"/>
                    <measurement group_id="B2" value="3.42" spread="3.40"/>
                    <measurement group_id="B3" value="3.18" spread="3.47"/>
                    <measurement group_id="B4" value="3.58" spread="3.51"/>
                    <measurement group_id="B5" value="3.22" spread="3.17"/>
                    <measurement group_id="B6" value="3.16" spread="3.08"/>
                    <measurement group_id="B7" value="3.29" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of micturitions/24 h</title>
          <description>A micturition was defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="418"/>
                    <count group_id="B2" value="409"/>
                    <count group_id="B3" value="411"/>
                    <count group_id="B4" value="415"/>
                    <count group_id="B5" value="827"/>
                    <count group_id="B6" value="826"/>
                    <count group_id="B7" value="3306"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.97" spread="2.86"/>
                    <measurement group_id="B2" value="10.81" spread="2.63"/>
                    <measurement group_id="B3" value="11.19" spread="3.27"/>
                    <measurement group_id="B4" value="10.76" spread="2.47"/>
                    <measurement group_id="B5" value="10.73" spread="2.88"/>
                    <measurement group_id="B6" value="10.74" spread="2.36"/>
                    <measurement group_id="B7" value="10.84" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean volume voided per micturition</title>
          <description>The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="414"/>
                    <count group_id="B2" value="407"/>
                    <count group_id="B3" value="409"/>
                    <count group_id="B4" value="413"/>
                    <count group_id="B5" value="823"/>
                    <count group_id="B6" value="824"/>
                    <count group_id="B7" value="3290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.94" spread="58.78"/>
                    <measurement group_id="B2" value="152.46" spread="60.96"/>
                    <measurement group_id="B3" value="155.31" spread="60.78"/>
                    <measurement group_id="B4" value="151.94" spread="59.29"/>
                    <measurement group_id="B5" value="159.32" spread="58.29"/>
                    <measurement group_id="B6" value="153.57" spread="59.67"/>
                    <measurement group_id="B7" value="155.43" spread="59.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of incontinence episodes/week</title>
          <description>The number of incontinence episodes was calculated from total number of incontinence episodes recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="418"/>
                    <count group_id="B2" value="409"/>
                    <count group_id="B3" value="411"/>
                    <count group_id="B4" value="415"/>
                    <count group_id="B5" value="827"/>
                    <count group_id="B6" value="826"/>
                    <count group_id="B7" value="3306"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="23.6"/>
                    <measurement group_id="B2" value="23.5" spread="23.6"/>
                    <measurement group_id="B3" value="21.7" spread="23.8"/>
                    <measurement group_id="B4" value="24.8" spread="24.5"/>
                    <measurement group_id="B5" value="22.1" spread="21.7"/>
                    <measurement group_id="B6" value="21.7" spread="21.3"/>
                    <measurement group_id="B7" value="22.7" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of urgency incontinence episodes/24 h</title>
          <description>An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes per 24 hours was calculated from number of times a participant recorded an urgency incontinence episode per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>urgency incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="415"/>
                    <count group_id="B2" value="407"/>
                    <count group_id="B3" value="405"/>
                    <count group_id="B4" value="414"/>
                    <count group_id="B5" value="823"/>
                    <count group_id="B6" value="822"/>
                    <count group_id="B7" value="3286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.14" spread="3.23"/>
                    <measurement group_id="B2" value="3.00" spread="3.09"/>
                    <measurement group_id="B3" value="2.89" spread="3.31"/>
                    <measurement group_id="B4" value="3.23" spread="3.34"/>
                    <measurement group_id="B5" value="2.85" spread="2.81"/>
                    <measurement group_id="B6" value="2.80" spread="2.64"/>
                    <measurement group_id="B7" value="2.94" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of urgency incontinence episodes/week</title>
          <description>The number of urgency incontinence episodes was number of times a participant recorded an urgency incontinence episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>urgency incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="415"/>
                    <count group_id="B2" value="407"/>
                    <count group_id="B3" value="405"/>
                    <count group_id="B4" value="414"/>
                    <count group_id="B5" value="823"/>
                    <count group_id="B6" value="822"/>
                    <count group_id="B7" value="3286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.7" spread="22.6"/>
                    <measurement group_id="B2" value="20.6" spread="21.4"/>
                    <measurement group_id="B3" value="19.8" spread="22.7"/>
                    <measurement group_id="B4" value="22.4" spread="23.3"/>
                    <measurement group_id="B5" value="19.5" spread="19.3"/>
                    <measurement group_id="B6" value="19.2" spread="18.2"/>
                    <measurement group_id="B7" value="20.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of urgency episodes (Grade 3 or 4)/24 h</title>
          <description>An urgency episode (Grade 3 or 4) was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer; it was recorded when a micturition or incontinence episode was recorded and the severity of urinary urgency recorded was 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>urgency episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="417"/>
                    <count group_id="B2" value="409"/>
                    <count group_id="B3" value="411"/>
                    <count group_id="B4" value="415"/>
                    <count group_id="B5" value="827"/>
                    <count group_id="B6" value="826"/>
                    <count group_id="B7" value="3305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.52" spread="4.05"/>
                    <measurement group_id="B2" value="6.22" spread="3.89"/>
                    <measurement group_id="B3" value="6.46" spread="4.88"/>
                    <measurement group_id="B4" value="6.48" spread="3.88"/>
                    <measurement group_id="B5" value="6.22" spread="3.70"/>
                    <measurement group_id="B6" value="6.22" spread="3.56"/>
                    <measurement group_id="B7" value="6.32" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of nocturia episodes/24 h</title>
          <description>A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patients gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24hr was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>nocturia episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="368"/>
                    <count group_id="B2" value="344"/>
                    <count group_id="B3" value="356"/>
                    <count group_id="B4" value="352"/>
                    <count group_id="B5" value="710"/>
                    <count group_id="B6" value="704"/>
                    <count group_id="B7" value="2834"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.57" spread="1.06"/>
                    <measurement group_id="B2" value="1.53" spread="1.02"/>
                    <measurement group_id="B3" value="1.59" spread="1.09"/>
                    <measurement group_id="B4" value="1.59" spread="0.96"/>
                    <measurement group_id="B5" value="1.56" spread="1.07"/>
                    <measurement group_id="B6" value="1.52" spread="0.97"/>
                    <measurement group_id="B7" value="1.56" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of nocturia episodes/week</title>
          <description>The number of nocturia episodes was calculated from sun of each nocturia episodes recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>nocturia episode</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="368"/>
                    <count group_id="B2" value="344"/>
                    <count group_id="B3" value="356"/>
                    <count group_id="B4" value="352"/>
                    <count group_id="B5" value="710"/>
                    <count group_id="B6" value="704"/>
                    <count group_id="B7" value="2834"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="7.4"/>
                    <measurement group_id="B2" value="10.6" spread="7.1"/>
                    <measurement group_id="B3" value="11.0" spread="7.6"/>
                    <measurement group_id="B4" value="11.0" spread="6.6"/>
                    <measurement group_id="B5" value="10.8" spread="7.4"/>
                    <measurement group_id="B6" value="10.5" spread="6.7"/>
                    <measurement group_id="B7" value="10.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of pads used/24 h</title>
          <description>The mean number of pads used per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>pads</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="256"/>
                    <count group_id="B2" value="252"/>
                    <count group_id="B3" value="251"/>
                    <count group_id="B4" value="262"/>
                    <count group_id="B5" value="513"/>
                    <count group_id="B6" value="511"/>
                    <count group_id="B7" value="2045"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.87" spread="2.99"/>
                    <measurement group_id="B2" value="2.86" spread="2.70"/>
                    <measurement group_id="B3" value="2.62" spread="3.18"/>
                    <measurement group_id="B4" value="2.87" spread="3.14"/>
                    <measurement group_id="B5" value="2.50" spread="2.58"/>
                    <measurement group_id="B6" value="2.58" spread="2.39"/>
                    <measurement group_id="B7" value="2.67" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pads used/week</title>
          <description>The number of pads used was calculated from sum of each record with a new pad checked on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data were included in the analysis.</population>
          <units>pads</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="256"/>
                    <count group_id="B2" value="252"/>
                    <count group_id="B3" value="251"/>
                    <count group_id="B4" value="262"/>
                    <count group_id="B5" value="513"/>
                    <count group_id="B6" value="511"/>
                    <count group_id="B7" value="2045"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="20.9"/>
                    <measurement group_id="B2" value="19.6" spread="18.7"/>
                    <measurement group_id="B3" value="17.9" spread="21.7"/>
                    <measurement group_id="B4" value="19.9" spread="21.8"/>
                    <measurement group_id="B5" value="17.1" spread="17.7"/>
                    <measurement group_id="B6" value="17.7" spread="16.4"/>
                    <measurement group_id="B7" value="19.3" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours</title>
        <description>An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS comprised all RAS patients who took ≥ 1 dose of double-blind treatment after randomization, reported ≥ 1 micturition in the baseline diary and ≥ 1 micturition postbaseline, reported ≥ 1 incontinence episode in the baseline diary and excluded participants from one site. Last observation carried forward (LOCF) was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours</title>
          <description>An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
          <population>FAS comprised all RAS patients who took ≥ 1 dose of double-blind treatment after randomization, reported ≥ 1 micturition in the baseline diary and ≥ 1 micturition postbaseline, reported ≥ 1 incontinence episode in the baseline diary and excluded participants from one site. Last observation carried forward (LOCF) was used for EoT.</population>
          <units>incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="413"/>
                <count group_id="O5" value="823"/>
                <count group_id="O6" value="816"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.10"/>
                    <measurement group_id="O2" value="-1.70" spread="0.10"/>
                    <measurement group_id="O3" value="-1.76" spread="0.10"/>
                    <measurement group_id="O4" value="-1.79" spread="0.10"/>
                    <measurement group_id="O5" value="-2.04" spread="0.07"/>
                    <measurement group_id="O6" value="-1.98" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Stratified rank ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Stratified rank ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Stratified rank ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours</title>
        <description>A micturition was defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours</title>
          <description>A micturition was defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</description>
          <population>FAS. LOCF was used for EoT.</population>
          <units>micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="413"/>
                <count group_id="O5" value="823"/>
                <count group_id="O6" value="816"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.12"/>
                    <measurement group_id="O2" value="-2.00" spread="0.12"/>
                    <measurement group_id="O3" value="-2.03" spread="0.12"/>
                    <measurement group_id="O4" value="-2.20" spread="0.12"/>
                    <measurement group_id="O5" value="-2.49" spread="0.08"/>
                    <measurement group_id="O6" value="-2.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in Mean Volume Voided Per Micturition</title>
        <description>The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in Mean Volume Voided Per Micturition</title>
          <description>The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.</description>
          <population>FAS. LOCF was used for EoT.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="407"/>
                <count group_id="O3" value="408"/>
                <count group_id="O4" value="411"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="821"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="2.55"/>
                    <measurement group_id="O2" value="13.32" spread="2.57"/>
                    <measurement group_id="O3" value="21.99" spread="2.57"/>
                    <measurement group_id="O4" value="30.99" spread="2.56"/>
                    <measurement group_id="O5" value="34.84" spread="1.81"/>
                    <measurement group_id="O6" value="39.73" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.219</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>10.00</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>8.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.61</ci_lower_limit>
            <ci_upper_limit>14.89</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>21.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.35</ci_lower_limit>
            <ci_upper_limit>27.68</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>17.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.58</ci_lower_limit>
            <ci_upper_limit>23.90</ci_upper_limit>
            <estimate_desc>Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score</title>
        <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score</title>
          <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.</description>
          <population>FAS. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="392"/>
                <count group_id="O3" value="398"/>
                <count group_id="O4" value="399"/>
                <count group_id="O5" value="800"/>
                <count group_id="O6" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.45" spread="0.98"/>
                    <measurement group_id="O2" value="-23.93" spread="0.99"/>
                    <measurement group_id="O3" value="-26.14" spread="0.98"/>
                    <measurement group_id="O4" value="-26.44" spread="0.98"/>
                    <measurement group_id="O5" value="-31.06" spread="0.69"/>
                    <measurement group_id="O6" value="-32.24" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-4.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.98</ci_lower_limit>
            <ci_upper_limit>-2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-5.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.17</ci_lower_limit>
            <ci_upper_limit>-3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-7.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.50</ci_lower_limit>
            <ci_upper_limit>-4.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-6.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.46</ci_lower_limit>
            <ci_upper_limit>-3.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)</title>
        <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)</title>
          <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
          <population>FAS. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="398"/>
                <count group_id="O4" value="399"/>
                <count group_id="O5" value="798"/>
                <count group_id="O6" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.11"/>
                    <measurement group_id="O2" value="2.16" spread="0.11"/>
                    <measurement group_id="O3" value="2.18" spread="0.11"/>
                    <measurement group_id="O4" value="2.28" spread="0.11"/>
                    <measurement group_id="O5" value="2.53" spread="0.08"/>
                    <measurement group_id="O6" value="2.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt; 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>No adjustment for multiplicity was made for this comparison.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT</title>
        <description>The number of incontinence episodes was calculated as the total number of incontinence episodes on valid diary days recorded during the 7-day micturition diary period.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT</title>
          <description>The number of incontinence episodes was calculated as the total number of incontinence episodes on valid diary days recorded during the 7-day micturition diary period.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.09" spread="1.17"/>
                    <measurement group_id="O2" value="15.65" spread="1.08"/>
                    <measurement group_id="O3" value="12.90" spread="1.06"/>
                    <measurement group_id="O4" value="15.31" spread="1.11"/>
                    <measurement group_id="O5" value="12.51" spread="0.67"/>
                    <measurement group_id="O6" value="11.44" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.45" spread="1.12"/>
                    <measurement group_id="O2" value="12.84" spread="1.05"/>
                    <measurement group_id="O3" value="11.31" spread="1.09"/>
                    <measurement group_id="O4" value="12.19" spread="1.06"/>
                    <measurement group_id="O5" value="9.70" spread="0.65"/>
                    <measurement group_id="O6" value="9.33" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.06" spread="1.17"/>
                    <measurement group_id="O2" value="10.60" spread="0.98"/>
                    <measurement group_id="O3" value="9.50" spread="0.98"/>
                    <measurement group_id="O4" value="11.25" spread="1.03"/>
                    <measurement group_id="O5" value="7.62" spread="0.57"/>
                    <measurement group_id="O6" value="8.21" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.70" spread="1.08"/>
                    <measurement group_id="O2" value="11.19" spread="0.95"/>
                    <measurement group_id="O3" value="9.79" spread="0.94"/>
                    <measurement group_id="O4" value="11.21" spread="0.98"/>
                    <measurement group_id="O5" value="8.02" spread="0.55"/>
                    <measurement group_id="O6" value="8.18" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes</title>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.23" spread="0.66"/>
                    <measurement group_id="O2" value="-7.59" spread="0.66"/>
                    <measurement group_id="O3" value="-8.99" spread="0.67"/>
                    <measurement group_id="O4" value="-8.92" spread="0.67"/>
                    <measurement group_id="O5" value="-9.62" spread="0.47"/>
                    <measurement group_id="O6" value="-10.51" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.79" spread="0.71"/>
                    <measurement group_id="O2" value="-10.57" spread="0.72"/>
                    <measurement group_id="O3" value="-10.97" spread="0.72"/>
                    <measurement group_id="O4" value="-11.89" spread="0.72"/>
                    <measurement group_id="O5" value="-12.53" spread="0.50"/>
                    <measurement group_id="O6" value="-12.78" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.05" spread="0.72"/>
                    <measurement group_id="O2" value="-12.33" spread="0.72"/>
                    <measurement group_id="O3" value="-12.58" spread="0.72"/>
                    <measurement group_id="O4" value="-12.75" spread="0.71"/>
                    <measurement group_id="O5" value="-14.50" spread="0.51"/>
                    <measurement group_id="O6" value="-13.94" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.42" spread="0.68"/>
                    <measurement group_id="O2" value="-11.93" spread="0.68"/>
                    <measurement group_id="O3" value="-12.39" spread="0.68"/>
                    <measurement group_id="O4" value="-12.65" spread="0.68"/>
                    <measurement group_id="O5" value="-14.29" spread="0.48"/>
                    <measurement group_id="O6" value="-13.98" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>least squares mean difference</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.27</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>least square mean difference</param_type>
            <param_value>-2.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours</title>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours</title>
          <population>FAS participants with available data at each time point were included in the analysis.</population>
          <units>incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.10"/>
                    <measurement group_id="O2" value="-1.07" spread="0.10"/>
                    <measurement group_id="O3" value="-1.24" spread="0.10"/>
                    <measurement group_id="O4" value="-1.24" spread="0.10"/>
                    <measurement group_id="O5" value="-1.38" spread="0.07"/>
                    <measurement group_id="O6" value="-1.50" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.10"/>
                    <measurement group_id="O2" value="-1.51" spread="0.10"/>
                    <measurement group_id="O3" value="-1.57" spread="0.10"/>
                    <measurement group_id="O4" value="-1.66" spread="0.10"/>
                    <measurement group_id="O5" value="-1.79" spread="0.07"/>
                    <measurement group_id="O6" value="-1.84" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.11"/>
                    <measurement group_id="O2" value="-1.76" spread="0.11"/>
                    <measurement group_id="O3" value="-1.81" spread="0.11"/>
                    <measurement group_id="O4" value="-1.80" spread="0.10"/>
                    <measurement group_id="O5" value="-2.08" spread="0.07"/>
                    <measurement group_id="O6" value="-1.98" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours</title>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS participants with available data at each time point data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours</title>
          <population>FAS participants with available data at each time point data were included in the analysis.</population>
          <units>micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.11"/>
                    <measurement group_id="O2" value="-1.46" spread="0.11"/>
                    <measurement group_id="O3" value="-1.44" spread="0.11"/>
                    <measurement group_id="O4" value="-1.39" spread="0.11"/>
                    <measurement group_id="O5" value="-1.67" spread="0.08"/>
                    <measurement group_id="O6" value="-1.91" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.11"/>
                    <measurement group_id="O2" value="-1.95" spread="0.12"/>
                    <measurement group_id="O3" value="-1.89" spread="0.12"/>
                    <measurement group_id="O4" value="-1.84" spread="0.12"/>
                    <measurement group_id="O5" value="-2.23" spread="0.08"/>
                    <measurement group_id="O6" value="-2.42" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="0.12"/>
                    <measurement group_id="O2" value="-2.01" spread="0.12"/>
                    <measurement group_id="O3" value="-2.03" spread="0.12"/>
                    <measurement group_id="O4" value="-2.22" spread="0.12"/>
                    <measurement group_id="O5" value="-2.47" spread="0.08"/>
                    <measurement group_id="O6" value="-2.60" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition</title>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition</title>
          <population>FAS participants with available data at each time point were included in the analysis.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="398"/>
                    <count group_id="O3" value="399"/>
                    <count group_id="O4" value="395"/>
                    <count group_id="O5" value="798"/>
                    <count group_id="O6" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="2.13"/>
                    <measurement group_id="O2" value="10.08" spread="2.14"/>
                    <measurement group_id="O3" value="15.52" spread="2.14"/>
                    <measurement group_id="O4" value="24.23" spread="2.15"/>
                    <measurement group_id="O5" value="25.54" spread="1.51"/>
                    <measurement group_id="O6" value="28.99" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="387"/>
                    <count group_id="O5" value="770"/>
                    <count group_id="O6" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="2.48"/>
                    <measurement group_id="O2" value="10.96" spread="2.52"/>
                    <measurement group_id="O3" value="17.73" spread="2.53"/>
                    <measurement group_id="O4" value="27.55" spread="2.50"/>
                    <measurement group_id="O5" value="32.94" spread="1.78"/>
                    <measurement group_id="O6" value="36.51" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="364"/>
                    <count group_id="O4" value="378"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.70" spread="2.70"/>
                    <measurement group_id="O2" value="12.88" spread="2.74"/>
                    <measurement group_id="O3" value="22.40" spread="2.73"/>
                    <measurement group_id="O4" value="31.89" spread="2.68"/>
                    <measurement group_id="O5" value="35.52" spread="1.90"/>
                    <measurement group_id="O6" value="41.28" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in Corrected Micturition Frequency</title>
        <description>Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in Corrected Micturition Frequency</title>
          <description>Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline.</description>
          <population>FAS. LOCF was used for EoT.</population>
          <units>micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="413"/>
                <count group_id="O5" value="823"/>
                <count group_id="O6" value="816"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.24"/>
                    <measurement group_id="O2" value="-0.17" spread="0.24"/>
                    <measurement group_id="O3" value="-0.97" spread="0.24"/>
                    <measurement group_id="O4" value="-1.28" spread="0.24"/>
                    <measurement group_id="O5" value="-1.10" spread="0.17"/>
                    <measurement group_id="O6" value="-1.52" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.520</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.413</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean diffrence</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT</title>
        <description>An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the number of times a participant recorded an urgency incontinence episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 urgency incontinence episode at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT</title>
          <description>An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the number of times a participant recorded an urgency incontinence episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 urgency incontinence episode at baseline were included in the analysis.</population>
          <units>urgency incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="404"/>
                    <count group_id="O3" value="396"/>
                    <count group_id="O4" value="401"/>
                    <count group_id="O5" value="813"/>
                    <count group_id="O6" value="806"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="1.10"/>
                    <measurement group_id="O2" value="13.36" spread="0.99"/>
                    <measurement group_id="O3" value="11.46" spread="1.00"/>
                    <measurement group_id="O4" value="13.19" spread="1.06"/>
                    <measurement group_id="O5" value="10.22" spread="0.58"/>
                    <measurement group_id="O6" value="9.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="780"/>
                    <count group_id="O6" value="765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.77" spread="1.07"/>
                    <measurement group_id="O2" value="10.65" spread="0.94"/>
                    <measurement group_id="O3" value="10.09" spread="1.02"/>
                    <measurement group_id="O4" value="10.41" spread="1.00"/>
                    <measurement group_id="O5" value="7.58" spread="0.53"/>
                    <measurement group_id="O6" value="7.31" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="367"/>
                    <count group_id="O3" value="363"/>
                    <count group_id="O4" value="378"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="746"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" spread="1.09"/>
                    <measurement group_id="O2" value="8.84" spread="0.89"/>
                    <measurement group_id="O3" value="8.32" spread="0.94"/>
                    <measurement group_id="O4" value="9.29" spread="0.96"/>
                    <measurement group_id="O5" value="5.86" spread="0.46"/>
                    <measurement group_id="O6" value="6.27" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="409"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="400"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="819"/>
                    <count group_id="O6" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="1.00"/>
                    <measurement group_id="O2" value="9.37" spread="0.86"/>
                    <measurement group_id="O3" value="8.63" spread="0.89"/>
                    <measurement group_id="O4" value="9.29" spread="0.91"/>
                    <measurement group_id="O5" value="6.25" spread="0.45"/>
                    <measurement group_id="O6" value="6.15" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group &amp; the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65,≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate &amp; postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group &amp; the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65,≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate &amp; postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.288</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group &amp; the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65,≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate &amp; postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group &amp; the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65,≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate &amp; postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes</title>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. Only participants with ≥ 1 urgency incontinence episode at baseline were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes</title>
          <population>FAS participants with available data at each time point were included in the analysis. Only participants with ≥ 1 urgency incontinence episode at baseline were included in the analysis. LOCF was used for EoT.</population>
          <units>urgency incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="404"/>
                    <count group_id="O3" value="396"/>
                    <count group_id="O4" value="401"/>
                    <count group_id="O5" value="813"/>
                    <count group_id="O6" value="806"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.49" spread="0.63"/>
                    <measurement group_id="O2" value="-7.07" spread="0.63"/>
                    <measurement group_id="O3" value="-8.39" spread="0.63"/>
                    <measurement group_id="O4" value="-8.53" spread="0.63"/>
                    <measurement group_id="O5" value="-9.44" spread="0.44"/>
                    <measurement group_id="O6" value="-10.23" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="780"/>
                    <count group_id="O6" value="765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.30" spread="0.66"/>
                    <measurement group_id="O2" value="-9.93" spread="0.67"/>
                    <measurement group_id="O3" value="-10.07" spread="0.67"/>
                    <measurement group_id="O4" value="-11.10" spread="0.67"/>
                    <measurement group_id="O5" value="-12.18" spread="0.47"/>
                    <measurement group_id="O6" value="-12.18" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="367"/>
                    <count group_id="O3" value="363"/>
                    <count group_id="O4" value="378"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="746"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.96" spread="0.65"/>
                    <measurement group_id="O2" value="-11.39" spread="0.66"/>
                    <measurement group_id="O3" value="-11.66" spread="0.66"/>
                    <measurement group_id="O4" value="-12.10" spread="0.65"/>
                    <measurement group_id="O5" value="-13.87" spread="0.46"/>
                    <measurement group_id="O6" value="-13.53" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="409"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="400"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="819"/>
                    <count group_id="O6" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.26" spread="0.62"/>
                    <measurement group_id="O2" value="-11.03" spread="0.62"/>
                    <measurement group_id="O3" value="-11.44" spread="0.62"/>
                    <measurement group_id="O4" value="-12.03" spread="0.62"/>
                    <measurement group_id="O5" value="-13.64" spread="0.44"/>
                    <measurement group_id="O6" value="-13.64" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.10</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.70</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours</title>
        <description>The mean number of urgency incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours</title>
          <description>The mean number of urgency incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>urgency incontinence episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="404"/>
                    <count group_id="O3" value="396"/>
                    <count group_id="O4" value="401"/>
                    <count group_id="O5" value="813"/>
                    <count group_id="O6" value="806"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.09"/>
                    <measurement group_id="O2" value="-1.00" spread="0.09"/>
                    <measurement group_id="O3" value="-1.15" spread="0.09"/>
                    <measurement group_id="O4" value="-1.19" spread="0.09"/>
                    <measurement group_id="O5" value="-1.35" spread="0.06"/>
                    <measurement group_id="O6" value="-1.47" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="780"/>
                    <count group_id="O6" value="765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="0.10"/>
                    <measurement group_id="O2" value="-1.43" spread="0.10"/>
                    <measurement group_id="O3" value="-1.44" spread="0.10"/>
                    <measurement group_id="O4" value="-1.56" spread="0.10"/>
                    <measurement group_id="O5" value="-1.74" spread="0.07"/>
                    <measurement group_id="O6" value="-1.79" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="367"/>
                    <count group_id="O3" value="363"/>
                    <count group_id="O4" value="378"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="746"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.10"/>
                    <measurement group_id="O2" value="-1.63" spread="0.10"/>
                    <measurement group_id="O3" value="-1.67" spread="0.10"/>
                    <measurement group_id="O4" value="-1.72" spread="0.10"/>
                    <measurement group_id="O5" value="-1.99" spread="0.07"/>
                    <measurement group_id="O6" value="-1.93" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="409"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="400"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="819"/>
                    <count group_id="O6" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="0.09"/>
                    <measurement group_id="O2" value="-1.58" spread="0.09"/>
                    <measurement group_id="O3" value="-1.62" spread="0.09"/>
                    <measurement group_id="O4" value="-1.71" spread="0.09"/>
                    <measurement group_id="O5" value="-1.95" spread="0.06"/>
                    <measurement group_id="O6" value="-1.94" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Least squares mean diffeence</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50mg ) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Stratified rank ANCOVA</method>
            <param_type>Standard Error of the Mean</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>05</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours</title>
        <description>An urgency episode was a complaint of a sudden, compelling desire to pass urine, which was difficult to defer; it was recorded when a micturition or incontinence episode was recorded and the severity of urinary urgency recorded was 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 urgency episode at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours</title>
          <description>An urgency episode was a complaint of a sudden, compelling desire to pass urine, which was difficult to defer; it was recorded when a micturition or incontinence episode was recorded and the severity of urinary urgency recorded was 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 urgency episode at baseline were included in the analysis.</population>
          <units>urgency episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.15"/>
                    <measurement group_id="O2" value="-1.95" spread="0.14"/>
                    <measurement group_id="O3" value="-1.91" spread="0.15"/>
                    <measurement group_id="O4" value="-2.14" spread="0.15"/>
                    <measurement group_id="O5" value="-2.42" spread="0.10"/>
                    <measurement group_id="O6" value="-2.66" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.15"/>
                    <measurement group_id="O2" value="-2.54" spread="0.15"/>
                    <measurement group_id="O3" value="-2.43" spread="0.15"/>
                    <measurement group_id="O4" value="-2.90" spread="0.15"/>
                    <measurement group_id="O5" value="-3.13" spread="0.11"/>
                    <measurement group_id="O6" value="-3.28" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="0.16"/>
                    <measurement group_id="O2" value="-2.85" spread="0.16"/>
                    <measurement group_id="O3" value="-2.70" spread="0.16"/>
                    <measurement group_id="O4" value="-3.11" spread="0.16"/>
                    <measurement group_id="O5" value="-3.45" spread="0.11"/>
                    <measurement group_id="O6" value="-3.50" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="0.15"/>
                    <measurement group_id="O2" value="-2.74" spread="0.15"/>
                    <measurement group_id="O3" value="-2.63" spread="0.15"/>
                    <measurement group_id="O4" value="-3.05" spread="0.15"/>
                    <measurement group_id="O5" value="-3.38" spread="0.11"/>
                    <measurement group_id="O6" value="-3.51" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT</title>
        <description>A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant went to bed with the intention to sleep until the time the patients got up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT</title>
          <description>A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant went to bed with the intention to sleep until the time the patients got up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
          <units>nocturia episodes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="341"/>
                    <count group_id="O3" value="349"/>
                    <count group_id="O4" value="341"/>
                    <count group_id="O5" value="705"/>
                    <count group_id="O6" value="693"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" spread="0.43"/>
                    <measurement group_id="O2" value="8.46" spread="0.36"/>
                    <measurement group_id="O3" value="9.11" spread="0.47"/>
                    <measurement group_id="O4" value="9.22" spread="0.42"/>
                    <measurement group_id="O5" value="8.40" spread="0.25"/>
                    <measurement group_id="O6" value="8.09" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="349"/>
                    <count group_id="O2" value="327"/>
                    <count group_id="O3" value="336"/>
                    <count group_id="O4" value="329"/>
                    <count group_id="O5" value="676"/>
                    <count group_id="O6" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread="0.44"/>
                    <measurement group_id="O2" value="8.07" spread="0.34"/>
                    <measurement group_id="O3" value="8.61" spread="0.45"/>
                    <measurement group_id="O4" value="8.37" spread="0.38"/>
                    <measurement group_id="O5" value="7.63" spread="0.25"/>
                    <measurement group_id="O6" value="7.11" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="321"/>
                    <count group_id="O4" value="320"/>
                    <count group_id="O5" value="652"/>
                    <count group_id="O6" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91" spread="0.43"/>
                    <measurement group_id="O2" value="7.99" spread="0.37"/>
                    <measurement group_id="O3" value="8.34" spread="0.48"/>
                    <measurement group_id="O4" value="8.17" spread="0.39"/>
                    <measurement group_id="O5" value="7.26" spread="0.24"/>
                    <measurement group_id="O6" value="6.67" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="353"/>
                    <count group_id="O4" value="350"/>
                    <count group_id="O5" value="708"/>
                    <count group_id="O6" value="697"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.83" spread="0.42"/>
                    <measurement group_id="O2" value="7.79" spread="0.35"/>
                    <measurement group_id="O3" value="8.14" spread="0.45"/>
                    <measurement group_id="O4" value="8.12" spread="0.37"/>
                    <measurement group_id="O5" value="7.33" spread="0.24"/>
                    <measurement group_id="O6" value="6.67" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes</title>
        <time_frame>Baseline and weeks 4, 8, 12, and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
          <units>nocturia episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="341"/>
                    <count group_id="O3" value="349"/>
                    <count group_id="O4" value="341"/>
                    <count group_id="O5" value="705"/>
                    <count group_id="O6" value="693"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.27"/>
                    <measurement group_id="O2" value="-2.25" spread="0.28"/>
                    <measurement group_id="O3" value="-1.80" spread="0.27"/>
                    <measurement group_id="O4" value="-1.79" spread="0.28"/>
                    <measurement group_id="O5" value="-2.39" spread="0.19"/>
                    <measurement group_id="O6" value="-2.50" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="349"/>
                    <count group_id="O2" value="327"/>
                    <count group_id="O3" value="336"/>
                    <count group_id="O4" value="329"/>
                    <count group_id="O5" value="676"/>
                    <count group_id="O6" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="0.27"/>
                    <measurement group_id="O2" value="-2.70" spread="0.28"/>
                    <measurement group_id="O3" value="-2.41" spread="0.28"/>
                    <measurement group_id="O4" value="-2.60" spread="0.28"/>
                    <measurement group_id="O5" value="-3.13" spread="0.20"/>
                    <measurement group_id="O6" value="-3.48" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="321"/>
                    <count group_id="O4" value="320"/>
                    <count group_id="O5" value="652"/>
                    <count group_id="O6" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="0.29"/>
                    <measurement group_id="O2" value="-2.77" spread="0.30"/>
                    <measurement group_id="O3" value="-2.73" spread="0.29"/>
                    <measurement group_id="O4" value="-2.89" spread="0.29"/>
                    <measurement group_id="O5" value="-3.49" spread="0.21"/>
                    <measurement group_id="O6" value="-3.96" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="353"/>
                    <count group_id="O4" value="350"/>
                    <count group_id="O5" value="708"/>
                    <count group_id="O6" value="697"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="0.27"/>
                    <measurement group_id="O2" value="-2.91" spread="0.28"/>
                    <measurement group_id="O3" value="-2.75" spread="0.28"/>
                    <measurement group_id="O4" value="-2.81" spread="0.28"/>
                    <measurement group_id="O5" value="-3.42" spread="0.20"/>
                    <measurement group_id="O6" value="-3.96" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.88</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours</title>
        <description>The mean number of nocturia episodes per 24hr was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours</title>
          <description>The mean number of nocturia episodes per 24hr was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 nocturia episode at baseline were included in the analysis.</population>
          <units>nocturia episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="341"/>
                    <count group_id="O3" value="349"/>
                    <count group_id="O4" value="341"/>
                    <count group_id="O5" value="705"/>
                    <count group_id="O6" value="693"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.04"/>
                    <measurement group_id="O2" value="-0.31" spread="0.04"/>
                    <measurement group_id="O3" value="-0.25" spread="0.04"/>
                    <measurement group_id="O4" value="-0.24" spread="0.04"/>
                    <measurement group_id="O5" value="-0.33" spread="0.03"/>
                    <measurement group_id="O6" value="-0.35" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="349"/>
                    <count group_id="O2" value="327"/>
                    <count group_id="O3" value="336"/>
                    <count group_id="O4" value="329"/>
                    <count group_id="O5" value="676"/>
                    <count group_id="O6" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.04"/>
                    <measurement group_id="O2" value="-0.37" spread="0.04"/>
                    <measurement group_id="O3" value="-0.35" spread="0.04"/>
                    <measurement group_id="O4" value="-0.36" spread="0.04"/>
                    <measurement group_id="O5" value="-0.44" spread="0.03"/>
                    <measurement group_id="O6" value="-0.50" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="321"/>
                    <count group_id="O4" value="320"/>
                    <count group_id="O5" value="652"/>
                    <count group_id="O6" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.39" spread="0.04"/>
                    <measurement group_id="O4" value="-0.41" spread="0.04"/>
                    <measurement group_id="O5" value="-0.49" spread="0.03"/>
                    <measurement group_id="O6" value="-0.56" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatmemt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="353"/>
                    <count group_id="O4" value="350"/>
                    <count group_id="O5" value="708"/>
                    <count group_id="O6" value="697"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.04"/>
                    <measurement group_id="O2" value="-0.40" spread="0.04"/>
                    <measurement group_id="O3" value="-0.39" spread="0.04"/>
                    <measurement group_id="O4" value="-0.39" spread="0.04"/>
                    <measurement group_id="O5" value="-0.48" spread="0.03"/>
                    <measurement group_id="O6" value="-0.56" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.100</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pads Used at Weeks 4, 8, 12 and EoT</title>
        <description>The number of pads used was the number of times a participant recorded a new pad used on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Weeks 4, 8 and 12 (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pads Used at Weeks 4, 8, 12 and EoT</title>
          <description>The number of pads used was the number of times a participant recorded a new pad used on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
          <units>pads</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="250"/>
                    <count group_id="O3" value="247"/>
                    <count group_id="O4" value="257"/>
                    <count group_id="O5" value="506"/>
                    <count group_id="O6" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.62" spread="1.33"/>
                    <measurement group_id="O2" value="13.46" spread="1.24"/>
                    <measurement group_id="O3" value="10.05" spread="1.21"/>
                    <measurement group_id="O4" value="11.41" spread="1.23"/>
                    <measurement group_id="O5" value="9.71" spread="0.70"/>
                    <measurement group_id="O6" value="9.34" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="243"/>
                    <count group_id="O5" value="485"/>
                    <count group_id="O6" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75" spread="1.22"/>
                    <measurement group_id="O2" value="10.79" spread="1.05"/>
                    <measurement group_id="O3" value="9.53" spread="1.39"/>
                    <measurement group_id="O4" value="8.45" spread="1.03"/>
                    <measurement group_id="O5" value="8.07" spread="0.65"/>
                    <measurement group_id="O6" value="7.58" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="229"/>
                    <count group_id="O4" value="241"/>
                    <count group_id="O5" value="468"/>
                    <count group_id="O6" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.62" spread="1.21"/>
                    <measurement group_id="O2" value="9.65" spread="1.00"/>
                    <measurement group_id="O3" value="8.44" spread="1.26"/>
                    <measurement group_id="O4" value="8.21" spread="0.95"/>
                    <measurement group_id="O5" value="6.60" spread="0.58"/>
                    <measurement group_id="O6" value="6.64" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="252"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="262"/>
                    <count group_id="O5" value="510"/>
                    <count group_id="O6" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.29" spread="1.11"/>
                    <measurement group_id="O2" value="10.15" spread="0.97"/>
                    <measurement group_id="O3" value="8.16" spread="1.17"/>
                    <measurement group_id="O4" value="8.53" spread="0.94"/>
                    <measurement group_id="O5" value="7.04" spread="0.56"/>
                    <measurement group_id="O6" value="6.80" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.938</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.967</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Negative binomial regression</method>
            <param_type>Standard Error of the Mean</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (&lt;65, &gt;=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used</title>
        <time_frame>Baseline and weeks 4, 8, 12 and EOT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
          <units>pads</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="250"/>
                    <count group_id="O3" value="247"/>
                    <count group_id="O4" value="257"/>
                    <count group_id="O5" value="506"/>
                    <count group_id="O6" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="0.71"/>
                    <measurement group_id="O2" value="-5.68" spread="0.71"/>
                    <measurement group_id="O3" value="-7.83" spread="0.71"/>
                    <measurement group_id="O4" value="-8.23" spread="0.70"/>
                    <measurement group_id="O5" value="-7.61" spread="0.50"/>
                    <measurement group_id="O6" value="-8.58" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="243"/>
                    <count group_id="O5" value="485"/>
                    <count group_id="O6" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.24" spread="0.77"/>
                    <measurement group_id="O2" value="-8.44" spread="0.77"/>
                    <measurement group_id="O3" value="-8.43" spread="0.76"/>
                    <measurement group_id="O4" value="-10.67" spread="0.76"/>
                    <measurement group_id="O5" value="-9.49" spread="0.54"/>
                    <measurement group_id="O6" value="-10.59" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="229"/>
                    <count group_id="O4" value="241"/>
                    <count group_id="O5" value="468"/>
                    <count group_id="O6" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.29" spread="0.75"/>
                    <measurement group_id="O2" value="-9.06" spread="0.75"/>
                    <measurement group_id="O3" value="-9.41" spread="0.75"/>
                    <measurement group_id="O4" value="-10.80" spread="0.73"/>
                    <measurement group_id="O5" value="-10.66" spread="0.52"/>
                    <measurement group_id="O6" value="-11.23" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="252"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="262"/>
                    <count group_id="O5" value="510"/>
                    <count group_id="O6" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.60" spread="0.71"/>
                    <measurement group_id="O2" value="-8.76" spread="0.71"/>
                    <measurement group_id="O3" value="-9.80" spread="0.72"/>
                    <measurement group_id="O4" value="-10.63" spread="0.70"/>
                    <measurement group_id="O5" value="-10.67" spread="0.50"/>
                    <measurement group_id="O6" value="-11.21" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours</title>
        <description>The mean number of pads used per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
        <time_frame>Baseline and weeks 4, 8 and 12 (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours</title>
          <description>The mean number of pads used per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with ≥ 1 pad used at baseline were included in the analysis.</population>
          <units>pads</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="250"/>
                    <count group_id="O3" value="247"/>
                    <count group_id="O4" value="257"/>
                    <count group_id="O5" value="506"/>
                    <count group_id="O6" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.10"/>
                    <measurement group_id="O2" value="-0.81" spread="0.10"/>
                    <measurement group_id="O3" value="-1.12" spread="0.10"/>
                    <measurement group_id="O4" value="-1.19" spread="0.10"/>
                    <measurement group_id="O5" value="-1.09" spread="0.07"/>
                    <measurement group_id="O6" value="-1.23" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="243"/>
                    <count group_id="O5" value="485"/>
                    <count group_id="O6" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.11"/>
                    <measurement group_id="O2" value="-1.20" spread="0.11"/>
                    <measurement group_id="O3" value="-1.24" spread="0.11"/>
                    <measurement group_id="O4" value="-1.53" spread="0.11"/>
                    <measurement group_id="O5" value="-1.36" spread="0.08"/>
                    <measurement group_id="O6" value="-1.51" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="229"/>
                    <count group_id="O4" value="241"/>
                    <count group_id="O5" value="468"/>
                    <count group_id="O6" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.11"/>
                    <measurement group_id="O2" value="-1.30" spread="0.11"/>
                    <measurement group_id="O3" value="-1.37" spread="0.11"/>
                    <measurement group_id="O4" value="-1.56" spread="0.11"/>
                    <measurement group_id="O5" value="-1.54" spread="0.08"/>
                    <measurement group_id="O6" value="-1.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="252"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="262"/>
                    <count group_id="O5" value="510"/>
                    <count group_id="O6" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.10"/>
                    <measurement group_id="O2" value="-1.26" spread="0.10"/>
                    <measurement group_id="O3" value="-1.41" spread="0.10"/>
                    <measurement group_id="O4" value="-1.53" spread="0.10"/>
                    <measurement group_id="O5" value="-1.53" spread="0.07"/>
                    <measurement group_id="O6" value="-1.58" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.993</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.650</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT</title>
        <description>The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT</title>
          <description>The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>incontinence-free days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.13"/>
                    <measurement group_id="O2" value="2.48" spread="0.13"/>
                    <measurement group_id="O3" value="2.98" spread="0.13"/>
                    <measurement group_id="O4" value="2.74" spread="0.14"/>
                    <measurement group_id="O5" value="3.08" spread="0.10"/>
                    <measurement group_id="O6" value="3.37" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.14"/>
                    <measurement group_id="O2" value="3.17" spread="0.14"/>
                    <measurement group_id="O3" value="3.63" spread="0.15"/>
                    <measurement group_id="O4" value="3.31" spread="0.14"/>
                    <measurement group_id="O5" value="3.88" spread="0.10"/>
                    <measurement group_id="O6" value="4.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.15"/>
                    <measurement group_id="O2" value="3.69" spread="0.15"/>
                    <measurement group_id="O3" value="3.96" spread="0.15"/>
                    <measurement group_id="O4" value="3.68" spread="0.14"/>
                    <measurement group_id="O5" value="4.33" spread="0.10"/>
                    <measurement group_id="O6" value="4.25" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.14"/>
                    <measurement group_id="O2" value="3.51" spread="0.14"/>
                    <measurement group_id="O3" value="3.89" spread="0.14"/>
                    <measurement group_id="O4" value="3.61" spread="0.14"/>
                    <measurement group_id="O5" value="4.20" spread="0.10"/>
                    <measurement group_id="O6" value="4.23" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</title>
        <description>The number of days with &lt; 8 micturitions was the number of valid diary days during the 7-day micturition diary period with less than 8 micturitions per day.</description>
        <time_frame>Weeks 4, 8,12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</title>
          <description>The number of days with &lt; 8 micturitions was the number of valid diary days during the 7-day micturition diary period with less than 8 micturitions per day.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.10"/>
                    <measurement group_id="O2" value="1.74" spread="0.10"/>
                    <measurement group_id="O3" value="1.55" spread="0.10"/>
                    <measurement group_id="O4" value="1.86" spread="0.11"/>
                    <measurement group_id="O5" value="2.07" spread="0.08"/>
                    <measurement group_id="O6" value="2.11" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.10"/>
                    <measurement group_id="O2" value="2.08" spread="0.12"/>
                    <measurement group_id="O3" value="1.99" spread="0.11"/>
                    <measurement group_id="O4" value="2.22" spread="0.12"/>
                    <measurement group_id="O5" value="2.59" spread="0.09"/>
                    <measurement group_id="O6" value="2.70" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.11"/>
                    <measurement group_id="O2" value="2.31" spread="0.13"/>
                    <measurement group_id="O3" value="2.25" spread="0.12"/>
                    <measurement group_id="O4" value="2.49" spread="0.13"/>
                    <measurement group_id="O5" value="2.87" spread="0.09"/>
                    <measurement group_id="O6" value="2.95" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.11"/>
                    <measurement group_id="O2" value="2.28" spread="0.12"/>
                    <measurement group_id="O3" value="2.22" spread="0.12"/>
                    <measurement group_id="O4" value="2.49" spread="0.12"/>
                    <measurement group_id="O5" value="2.84" spread="0.09"/>
                    <measurement group_id="O6" value="2.92" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence-Free Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</title>
        <description>The number of incontinence-free days with &lt; 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with &lt; 8 micturitions per day.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence-Free Days With &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT</title>
          <description>The number of incontinence-free days with &lt; 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with &lt; 8 micturitions per day.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.07"/>
                    <measurement group_id="O2" value="0.84" spread="0.08"/>
                    <measurement group_id="O3" value="0.87" spread="0.08"/>
                    <measurement group_id="O4" value="0.91" spread="0.08"/>
                    <measurement group_id="O5" value="1.21" spread="0.07"/>
                    <measurement group_id="O6" value="1.32" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.08"/>
                    <measurement group_id="O2" value="1.20" spread="0.10"/>
                    <measurement group_id="O3" value="1.23" spread="0.10"/>
                    <measurement group_id="O4" value="1.31" spread="0.10"/>
                    <measurement group_id="O5" value="1.75" spread="0.08"/>
                    <measurement group_id="O6" value="1.89" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.09"/>
                    <measurement group_id="O2" value="1.47" spread="0.11"/>
                    <measurement group_id="O3" value="1.50" spread="0.11"/>
                    <measurement group_id="O4" value="1.60" spread="0.11"/>
                    <measurement group_id="O5" value="2.12" spread="0.09"/>
                    <measurement group_id="O6" value="2.15" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.08"/>
                    <measurement group_id="O2" value="1.40" spread="0.10"/>
                    <measurement group_id="O3" value="1.47" spread="0.10"/>
                    <measurement group_id="O4" value="1.59" spread="0.10"/>
                    <measurement group_id="O5" value="2.04" spread="0.08"/>
                    <measurement group_id="O6" value="2.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Overdispersed binomial regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)</title>
        <description>The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.</description>
        <time_frame>Baseline and weeks 4, 8, 12, EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT .</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)</title>
          <description>The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT .</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="791"/>
                    <count group_id="O6" value="791"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.06"/>
                    <measurement group_id="O2" value="-0.72" spread="0.06"/>
                    <measurement group_id="O3" value="-0.83" spread="0.06"/>
                    <measurement group_id="O4" value="-0.81" spread="0.06"/>
                    <measurement group_id="O5" value="-0.99" spread="0.04"/>
                    <measurement group_id="O6" value="-1.07" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="372"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="758"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.06"/>
                    <measurement group_id="O2" value="-1.07" spread="0.06"/>
                    <measurement group_id="O3" value="-1.12" spread="0.06"/>
                    <measurement group_id="O4" value="-1.18" spread="0.06"/>
                    <measurement group_id="O5" value="-1.32" spread="0.04"/>
                    <measurement group_id="O6" value="-1.48" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="375"/>
                    <count group_id="O5" value="739"/>
                    <count group_id="O6" value="735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.06"/>
                    <measurement group_id="O2" value="-1.23" spread="0.06"/>
                    <measurement group_id="O3" value="-1.34" spread="0.06"/>
                    <measurement group_id="O4" value="-1.32" spread="0.06"/>
                    <measurement group_id="O5" value="-1.57" spread="0.04"/>
                    <measurement group_id="O6" value="-1.72" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="393"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="801"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.06"/>
                    <measurement group_id="O2" value="-1.18" spread="0.06"/>
                    <measurement group_id="O3" value="-1.31" spread="0.06"/>
                    <measurement group_id="O4" value="-1.27" spread="0.06"/>
                    <measurement group_id="O5" value="-1.53" spread="0.04"/>
                    <measurement group_id="O6" value="-1.66" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score</title>
        <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion in the OAB-q (seen in this outcome measure) consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.</description>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score</title>
          <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion in the OAB-q (seen in this outcome measure) consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.84" spread="0.92"/>
                    <measurement group_id="O2" value="-17.05" spread="0.93"/>
                    <measurement group_id="O3" value="-18.98" spread="0.93"/>
                    <measurement group_id="O4" value="-19.53" spread="0.93"/>
                    <measurement group_id="O5" value="-23.46" spread="0.65"/>
                    <measurement group_id="O6" value="-25.19" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.35" spread="0.98"/>
                    <measurement group_id="O2" value="-22.79" spread="0.99"/>
                    <measurement group_id="O3" value="-23.54" spread="0.98"/>
                    <measurement group_id="O4" value="-24.69" spread="0.97"/>
                    <measurement group_id="O5" value="-29.10" spread="0.69"/>
                    <measurement group_id="O6" value="-30.04" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.94" spread="1.01"/>
                    <measurement group_id="O2" value="-24.44" spread="1.02"/>
                    <measurement group_id="O3" value="-26.80" spread="1.02"/>
                    <measurement group_id="O4" value="-26.72" spread="1.01"/>
                    <measurement group_id="O5" value="-31.70" spread="0.72"/>
                    <measurement group_id="O6" value="-33.15" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score</title>
        <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion in the OAB-q (seen in this outcome measure) consisted of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total HRQoL score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score</title>
          <description>The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion in the OAB-q (seen in this outcome measure) consisted of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total HRQoL score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="0.83"/>
                    <measurement group_id="O2" value="13.54" spread="0.83"/>
                    <measurement group_id="O3" value="15.28" spread="0.83"/>
                    <measurement group_id="O4" value="14.78" spread="0.83"/>
                    <measurement group_id="O5" value="17.46" spread="0.58"/>
                    <measurement group_id="O6" value="17.95" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.51" spread="0.88"/>
                    <measurement group_id="O2" value="17.95" spread="0.89"/>
                    <measurement group_id="O3" value="18.54" spread="0.88"/>
                    <measurement group_id="O4" value="18.57" spread="0.88"/>
                    <measurement group_id="O5" value="22.30" spread="0.62"/>
                    <measurement group_id="O6" value="22.45" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="0.92"/>
                    <measurement group_id="O2" value="19.59" spread="0.93"/>
                    <measurement group_id="O3" value="21.48" spread="0.92"/>
                    <measurement group_id="O4" value="20.54" spread="0.91"/>
                    <measurement group_id="O5" value="24.63" spread="0.65"/>
                    <measurement group_id="O6" value="24.93" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.37" spread="0.88"/>
                    <measurement group_id="O2" value="18.94" spread="0.89"/>
                    <measurement group_id="O3" value="21.00" spread="0.89"/>
                    <measurement group_id="O4" value="20.15" spread="0.89"/>
                    <measurement group_id="O5" value="23.96" spread="0.63"/>
                    <measurement group_id="O6" value="24.30" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>6.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>5.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.88</ci_lower_limit>
            <ci_upper_limit>7.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>5.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping</title>
        <description>The Coping score was calculated by adding 8 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping</title>
          <description>The Coping score was calculated by adding 8 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.74" spread="0.99"/>
                    <measurement group_id="O2" value="14.87" spread="1.00"/>
                    <measurement group_id="O3" value="17.68" spread="1.00"/>
                    <measurement group_id="O4" value="16.52" spread="1.00"/>
                    <measurement group_id="O5" value="19.31" spread="0.70"/>
                    <measurement group_id="O6" value="20.36" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.13" spread="1.04"/>
                    <measurement group_id="O2" value="20.64" spread="1.05"/>
                    <measurement group_id="O3" value="21.52" spread="1.04"/>
                    <measurement group_id="O4" value="21.69" spread="1.03"/>
                    <measurement group_id="O5" value="25.49" spread="0.74"/>
                    <measurement group_id="O6" value="25.85" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.17" spread="1.09"/>
                    <measurement group_id="O2" value="22.04" spread="1.10"/>
                    <measurement group_id="O3" value="24.94" spread="1.10"/>
                    <measurement group_id="O4" value="23.67" spread="1.09"/>
                    <measurement group_id="O5" value="28.32" spread="0.77"/>
                    <measurement group_id="O6" value="29.03" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.73" spread="1.05"/>
                    <measurement group_id="O2" value="21.28" spread="1.06"/>
                    <measurement group_id="O3" value="24.32" spread="1.05"/>
                    <measurement group_id="O4" value="23.25" spread="1.05"/>
                    <measurement group_id="O5" value="27.37" spread="0.74"/>
                    <measurement group_id="O6" value="28.12" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>6.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Lest squares mean difference</param_type>
            <param_value>4.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.34</ci_lower_limit>
            <ci_upper_limit>7.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>6.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.55</ci_lower_limit>
            <ci_upper_limit>8.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>6.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern</title>
        <description>The Concern score was calculated by adding 7 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern</title>
          <description>The Concern score was calculated by adding 7 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24" spread="0.95"/>
                    <measurement group_id="O2" value="15.89" spread="0.96"/>
                    <measurement group_id="O3" value="17.39" spread="0.95"/>
                    <measurement group_id="O4" value="17.18" spread="0.95"/>
                    <measurement group_id="O5" value="20.48" spread="0.67"/>
                    <measurement group_id="O6" value="21.09" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.10" spread="0.99"/>
                    <measurement group_id="O2" value="20.63" spread="1.01"/>
                    <measurement group_id="O3" value="20.55" spread="1.00"/>
                    <measurement group_id="O4" value="20.96" spread="0.99"/>
                    <measurement group_id="O5" value="25.26" spread="0.71"/>
                    <measurement group_id="O6" value="25.65" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.53" spread="1.03"/>
                    <measurement group_id="O2" value="22.37" spread="1.04"/>
                    <measurement group_id="O3" value="23.62" spread="1.04"/>
                    <measurement group_id="O4" value="23.19" spread="1.03"/>
                    <measurement group_id="O5" value="27.53" spread="0.73"/>
                    <measurement group_id="O6" value="28.24" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.98" spread="1.00"/>
                    <measurement group_id="O2" value="21.55" spread="1.01"/>
                    <measurement group_id="O3" value="23.07" spread="1.00"/>
                    <measurement group_id="O4" value="22.65" spread="1.00"/>
                    <measurement group_id="O5" value="26.89" spread="0.71"/>
                    <measurement group_id="O6" value="27.47" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>6.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>7.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>5.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.93</ci_lower_limit>
            <ci_upper_limit>7.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.01</ci_lower_limit>
            <ci_upper_limit>6.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep</title>
        <description>The Sleep score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep</title>
          <description>The Sleep score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" spread="0.95"/>
                    <measurement group_id="O2" value="12.70" spread="0.96"/>
                    <measurement group_id="O3" value="13.80" spread="0.96"/>
                    <measurement group_id="O4" value="13.08" spread="0.96"/>
                    <measurement group_id="O5" value="15.97" spread="0.68"/>
                    <measurement group_id="O6" value="16.66" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.58" spread="1.03"/>
                    <measurement group_id="O2" value="16.39" spread="1.05"/>
                    <measurement group_id="O3" value="17.33" spread="1.03"/>
                    <measurement group_id="O4" value="16.43" spread="1.03"/>
                    <measurement group_id="O5" value="20.29" spread="0.73"/>
                    <measurement group_id="O6" value="20.49" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" spread="1.05"/>
                    <measurement group_id="O2" value="18.04" spread="1.06"/>
                    <measurement group_id="O3" value="19.16" spread="1.06"/>
                    <measurement group_id="O4" value="18.35" spread="1.05"/>
                    <measurement group_id="O5" value="22.97" spread="0.74"/>
                    <measurement group_id="O6" value="22.76" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.17" spread="1.01"/>
                    <measurement group_id="O2" value="17.51" spread="1.02"/>
                    <measurement group_id="O3" value="19.11" spread="1.02"/>
                    <measurement group_id="O4" value="17.97" spread="1.01"/>
                    <measurement group_id="O5" value="22.39" spread="0.72"/>
                    <measurement group_id="O6" value="22.39" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>6.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>6.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>7.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social</title>
        <description>The Social score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social</title>
          <description>The Social score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="0.78"/>
                    <measurement group_id="O2" value="9.04" spread="0.79"/>
                    <measurement group_id="O3" value="10.19" spread="0.78"/>
                    <measurement group_id="O4" value="9.89" spread="0.78"/>
                    <measurement group_id="O5" value="11.55" spread="0.55"/>
                    <measurement group_id="O6" value="11.25" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="0.82"/>
                    <measurement group_id="O2" value="11.50" spread="0.83"/>
                    <measurement group_id="O3" value="12.34" spread="0.82"/>
                    <measurement group_id="O4" value="12.02" spread="0.81"/>
                    <measurement group_id="O5" value="14.89" spread="0.58"/>
                    <measurement group_id="O6" value="14.73" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.84" spread="0.83"/>
                    <measurement group_id="O2" value="13.43" spread="0.84"/>
                    <measurement group_id="O3" value="15.35" spread="0.84"/>
                    <measurement group_id="O4" value="13.74" spread="0.83"/>
                    <measurement group_id="O5" value="16.16" spread="0.59"/>
                    <measurement group_id="O6" value="16.08" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" spread="0.81"/>
                    <measurement group_id="O2" value="13.04" spread="0.81"/>
                    <measurement group_id="O3" value="14.87" spread="0.81"/>
                    <measurement group_id="O4" value="13.57" spread="0.81"/>
                    <measurement group_id="O5" value="15.84" spread="0.57"/>
                    <measurement group_id="O6" value="15.82" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>2.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>4.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>2.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>2.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.337</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT</title>
        <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
        <time_frame>Week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT</title>
          <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="13.9"/>
                    <measurement group_id="O3" value="15.1"/>
                    <measurement group_id="O4" value="13.5"/>
                    <measurement group_id="O5" value="19.8"/>
                    <measurement group_id="O6" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="40.5"/>
                    <measurement group_id="O5" value="39.8"/>
                    <measurement group_id="O6" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="26.5"/>
                    <measurement group_id="O4" value="25.8"/>
                    <measurement group_id="O5" value="22.2"/>
                    <measurement group_id="O6" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="8.9"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0.8"/>
                    <measurement group_id="O6" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="13.9"/>
                    <measurement group_id="O3" value="15.1"/>
                    <measurement group_id="O4" value="13.5"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="33.2"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="41.0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="26.3"/>
                    <measurement group_id="O5" value="22.6"/>
                    <measurement group_id="O6" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="13.4"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="9.6"/>
                    <measurement group_id="O5" value="7.9"/>
                    <measurement group_id="O6" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0.8"/>
                    <measurement group_id="O6" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="0.7"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EoT: Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PGIC Scale: Impression in General Health at Week 12 and EoT</title>
        <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
        <time_frame>Week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PGIC Scale: Impression in General Health at Week 12 and EoT</title>
          <description>The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="7.7"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="31.8"/>
                    <measurement group_id="O5" value="33.4"/>
                    <measurement group_id="O6" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="24.1"/>
                    <measurement group_id="O5" value="20.1"/>
                    <measurement group_id="O6" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="27.5"/>
                    <measurement group_id="O4" value="25.3"/>
                    <measurement group_id="O5" value="23.9"/>
                    <measurement group_id="O6" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="7.7"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="31.8"/>
                    <measurement group_id="O5" value="33.6"/>
                    <measurement group_id="O6" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="22.9"/>
                    <measurement group_id="O4" value="24.1"/>
                    <measurement group_id="O5" value="20.2"/>
                    <measurement group_id="O6" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment:No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="27.7"/>
                    <measurement group_id="O4" value="26.5"/>
                    <measurement group_id="O5" value="24.3"/>
                    <measurement group_id="O6" value="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="2.8"/>
                    <measurement group_id="O6" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.7"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility</title>
        <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility</title>
          <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="225"/>
                    <measurement group_id="O4" value="227"/>
                    <measurement group_id="O5" value="449"/>
                    <measurement group_id="O6" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to walk about -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; unable to walk about</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care</title>
        <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care</title>
          <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="336"/>
                    <measurement group_id="O4" value="319"/>
                    <measurement group_id="O5" value="652"/>
                    <measurement group_id="O6" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; unable to wash/dress myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; unable to wash/dress myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; unable to wash/dress myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; unable to wash/dress myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; unable to w/d</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to wash/dress myself -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; unable to wash/dress myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities</title>
        <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities</title>
          <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problems -&gt; No problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="228"/>
                    <measurement group_id="O3" value="219"/>
                    <measurement group_id="O4" value="223"/>
                    <measurement group_id="O5" value="434"/>
                    <measurement group_id="O6" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; Slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; Moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; Severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; unable to do usual activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt;unable to do usual activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt;unable to do usual activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; unable to do usual activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe problems -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; unable to do usu.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do usual activities -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; slight problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; moderate problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; severe problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; unable to do usual activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort</title>
        <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort</title>
          <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain/discomfort -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="153"/>
                    <measurement group_id="O4" value="154"/>
                    <measurement group_id="O5" value="290"/>
                    <measurement group_id="O6" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain/discomfort -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain/discomfort -&gt; moderate pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain/discomfort -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain/discomfort -&gt; extreme pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain/discomfort -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="117"/>
                    <measurement group_id="O6" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; moderate pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; exteme pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain/discomfort -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; moderate pain/discomf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; extreme pain/discomf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain/discomfort -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; moderate pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; extreme pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain/discomfort -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; moderate pain/discom.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; extreme pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme pain/discomfort -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; slight pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; moderate pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; severe pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; extreme pain/discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression</title>
        <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
        <time_frame>Baseline and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression</title>
          <description>The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</description>
          <population>FAS participants with available data were included in the analysis. LOCF was used for EoT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not anxious -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="187"/>
                    <measurement group_id="O4" value="166"/>
                    <measurement group_id="O5" value="360"/>
                    <measurement group_id="O6" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not anxious -&gt; slightly anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not anxious -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not anxious -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not anxious -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not anxious -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="122"/>
                    <measurement group_id="O6" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; slightly anx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly anxious -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; slightly anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately anxious -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; slightly anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely anxious -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; slightly anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely anxious -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; not anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; slightly anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; moderately anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; severely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; extremely anxious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data -&gt; no data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed</title>
        <description>The WPAI:SHP was a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes were expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.</description>
        <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed</title>
          <description>The WPAI:SHP was a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes were expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
          <units>percentage of work time missed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="274"/>
                    <count group_id="O6" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.98" spread="21.70"/>
                    <measurement group_id="O2" value="-0.33" spread="22.03"/>
                    <measurement group_id="O3" value="-1.72" spread="18.70"/>
                    <measurement group_id="O4" value="-2.47" spread="14.13"/>
                    <measurement group_id="O5" value="-2.06" spread="20.93"/>
                    <measurement group_id="O6" value="-2.59" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="277"/>
                    <count group_id="O6" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="21.61"/>
                    <measurement group_id="O2" value="-0.33" spread="22.03"/>
                    <measurement group_id="O3" value="-1.71" spread="18.64"/>
                    <measurement group_id="O4" value="-2.44" spread="14.03"/>
                    <measurement group_id="O5" value="-1.48" spread="21.95"/>
                    <measurement group_id="O6" value="-2.55" spread="19.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working</title>
        <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
          <units>percentage of impairment while working</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="271"/>
                    <count group_id="O6" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.27" spread="25.36"/>
                    <measurement group_id="O2" value="-14.96" spread="26.21"/>
                    <measurement group_id="O3" value="-12.25" spread="25.06"/>
                    <measurement group_id="O4" value="-10.85" spread="25.58"/>
                    <measurement group_id="O5" value="-14.69" spread="26.99"/>
                    <measurement group_id="O6" value="-13.07" spread="27.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="273"/>
                    <count group_id="O6" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.18" spread="25.28"/>
                    <measurement group_id="O2" value="-14.96" spread="26.21"/>
                    <measurement group_id="O3" value="-12.37" spread="25.01"/>
                    <measurement group_id="O4" value="-10.98" spread="25.68"/>
                    <measurement group_id="O5" value="-14.58" spread="26.92"/>
                    <measurement group_id="O6" value="-12.87" spread="27.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment</title>
        <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
          <units>percentage of overall work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="271"/>
                    <count group_id="O6" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.23" spread="25.66"/>
                    <measurement group_id="O2" value="-15.70" spread="26.54"/>
                    <measurement group_id="O3" value="-12.92" spread="26.71"/>
                    <measurement group_id="O4" value="-12.31" spread="26.91"/>
                    <measurement group_id="O5" value="-16.31" spread="29.06"/>
                    <measurement group_id="O6" value="-13.97" spread="29.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="273"/>
                    <count group_id="O6" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.14" spread="25.58"/>
                    <measurement group_id="O2" value="-15.70" spread="26.54"/>
                    <measurement group_id="O3" value="-13.05" spread="26.65"/>
                    <measurement group_id="O4" value="-12.42" spread="26.98"/>
                    <measurement group_id="O5" value="-16.07" spread="29.12"/>
                    <measurement group_id="O6" value="-13.76" spread="29.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment</title>
        <time_frame>Baseline and week 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment</title>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT. Only participants with both baseline and post-baseline values were included in the analysis.</population>
          <units>percentage of activity impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="358"/>
                    <count group_id="O3" value="365"/>
                    <count group_id="O4" value="373"/>
                    <count group_id="O5" value="730"/>
                    <count group_id="O6" value="731"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.49" spread="27.31"/>
                    <measurement group_id="O2" value="-16.89" spread="27.57"/>
                    <measurement group_id="O3" value="-14.99" spread="27.81"/>
                    <measurement group_id="O4" value="-16.19" spread="29.16"/>
                    <measurement group_id="O5" value="-19.60" spread="28.80"/>
                    <measurement group_id="O6" value="-18.92" spread="29.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="361"/>
                    <count group_id="O3" value="368"/>
                    <count group_id="O4" value="380"/>
                    <count group_id="O5" value="736"/>
                    <count group_id="O6" value="743"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.55" spread="27.19"/>
                    <measurement group_id="O2" value="-16.72" spread="27.82"/>
                    <measurement group_id="O3" value="-15.05" spread="27.95"/>
                    <measurement group_id="O4" value="-16.05" spread="28.95"/>
                    <measurement group_id="O5" value="-19.45" spread="28.80"/>
                    <measurement group_id="O6" value="-18.76" spread="29.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8 and 12 in TS-VAS</title>
        <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
        <time_frame>Baseline and week 4, 8 and 12</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8 and 12 in TS-VAS</title>
          <description>The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.</description>
          <population>FAS participants with available data at each time point were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="386"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="788"/>
                    <count group_id="O6" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.12"/>
                    <measurement group_id="O2" value="1.68" spread="0.12"/>
                    <measurement group_id="O3" value="1.77" spread="0.12"/>
                    <measurement group_id="O4" value="1.82" spread="0.12"/>
                    <measurement group_id="O5" value="2.06" spread="0.08"/>
                    <measurement group_id="O6" value="2.13" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="380"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="756"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.11"/>
                    <measurement group_id="O2" value="2.16" spread="0.12"/>
                    <measurement group_id="O3" value="2.09" spread="0.11"/>
                    <measurement group_id="O4" value="2.20" spread="0.11"/>
                    <measurement group_id="O5" value="2.48" spread="0.08"/>
                    <measurement group_id="O6" value="2.48" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="370"/>
                    <count group_id="O2" value="361"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="373"/>
                    <count group_id="O5" value="736"/>
                    <count group_id="O6" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.12"/>
                    <measurement group_id="O2" value="2.24" spread="0.12"/>
                    <measurement group_id="O3" value="2.23" spread="0.12"/>
                    <measurement group_id="O4" value="2.32" spread="0.12"/>
                    <measurement group_id="O5" value="2.58" spread="0.08"/>
                    <measurement group_id="O6" value="2.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="24.9"/>
                    <measurement group_id="O3" value="27.6"/>
                    <measurement group_id="O4" value="28.9"/>
                    <measurement group_id="O5" value="35.1"/>
                    <measurement group_id="O6" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="40.7"/>
                    <measurement group_id="O4" value="38.3"/>
                    <measurement group_id="O5" value="45.3"/>
                    <measurement group_id="O6" value="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="47.4"/>
                    <measurement group_id="O4" value="42.7"/>
                    <measurement group_id="O5" value="52.3"/>
                    <measurement group_id="O6" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="40.6"/>
                    <measurement group_id="O3" value="46.3"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="50.7"/>
                    <measurement group_id="O6" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="62.6"/>
                    <measurement group_id="O3" value="69.9"/>
                    <measurement group_id="O4" value="73.9"/>
                    <measurement group_id="O5" value="73.9"/>
                    <measurement group_id="O6" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="71.6"/>
                    <measurement group_id="O3" value="73.4"/>
                    <measurement group_id="O4" value="79.2"/>
                    <measurement group_id="O5" value="83.9"/>
                    <measurement group_id="O6" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                    <measurement group_id="O2" value="72.1"/>
                    <measurement group_id="O3" value="78.4"/>
                    <measurement group_id="O4" value="82.4"/>
                    <measurement group_id="O5" value="83.5"/>
                    <measurement group_id="O6" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3"/>
                    <measurement group_id="O2" value="71.2"/>
                    <measurement group_id="O3" value="77.1"/>
                    <measurement group_id="O4" value="81.2"/>
                    <measurement group_id="O5" value="82.8"/>
                    <measurement group_id="O6" value="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="790"/>
                    <count group_id="O6" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="52.8"/>
                    <measurement group_id="O3" value="59.7"/>
                    <measurement group_id="O4" value="61.7"/>
                    <measurement group_id="O5" value="62.9"/>
                    <measurement group_id="O6" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="757"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="62.2"/>
                    <measurement group_id="O3" value="65.3"/>
                    <measurement group_id="O4" value="66.2"/>
                    <measurement group_id="O5" value="71.5"/>
                    <measurement group_id="O6" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="738"/>
                    <count group_id="O6" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="62.4"/>
                    <measurement group_id="O3" value="69.1"/>
                    <measurement group_id="O4" value="71.7"/>
                    <measurement group_id="O5" value="76.3"/>
                    <measurement group_id="O6" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="800"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8"/>
                    <measurement group_id="O2" value="61.0"/>
                    <measurement group_id="O3" value="68.3"/>
                    <measurement group_id="O4" value="71.2"/>
                    <measurement group_id="O5" value="74.5"/>
                    <measurement group_id="O6" value="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.294</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with ≥ 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT).</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with ≥ 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT).</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="56.7"/>
                    <measurement group_id="O4" value="53.2"/>
                    <measurement group_id="O5" value="57.2"/>
                    <measurement group_id="O6" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="63.7"/>
                    <measurement group_id="O4" value="65.3"/>
                    <measurement group_id="O5" value="69.8"/>
                    <measurement group_id="O6" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="66.4"/>
                    <measurement group_id="O3" value="70.2"/>
                    <measurement group_id="O4" value="71.0"/>
                    <measurement group_id="O5" value="75.9"/>
                    <measurement group_id="O6" value="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="69.0"/>
                    <measurement group_id="O4" value="70.5"/>
                    <measurement group_id="O5" value="74.5"/>
                    <measurement group_id="O6" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.251</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with micturition frequency normalization was defined as any participant who had ≥ 8 micturitions/24 hours at baseline and &lt; 8 micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8 , 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with micturition frequency normalization was defined as any participant who had ≥ 8 micturitions/24 hours at baseline and &lt; 8 micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="25.4"/>
                    <measurement group_id="O4" value="31.1"/>
                    <measurement group_id="O5" value="36.0"/>
                    <measurement group_id="O6" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="34.5"/>
                    <measurement group_id="O4" value="37.0"/>
                    <measurement group_id="O5" value="45.3"/>
                    <measurement group_id="O6" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="42.3"/>
                    <measurement group_id="O3" value="40.7"/>
                    <measurement group_id="O4" value="44.9"/>
                    <measurement group_id="O5" value="50.8"/>
                    <measurement group_id="O6" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="42.1"/>
                    <measurement group_id="O3" value="40.1"/>
                    <measurement group_id="O4" value="45.0"/>
                    <measurement group_id="O5" value="51.3"/>
                    <measurement group_id="O6" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                    <count group_id="O5" value="817"/>
                    <count group_id="O6" value="810"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="13.1"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="17.7"/>
                    <measurement group_id="O5" value="23.9"/>
                    <measurement group_id="O6" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="386"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="29.8"/>
                    <measurement group_id="O4" value="28.2"/>
                    <measurement group_id="O5" value="36.6"/>
                    <measurement group_id="O6" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="369"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="379"/>
                    <count group_id="O5" value="754"/>
                    <count group_id="O6" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="35.0"/>
                    <measurement group_id="O4" value="31.9"/>
                    <measurement group_id="O5" value="42.4"/>
                    <measurement group_id="O6" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="413"/>
                    <count group_id="O5" value="823"/>
                    <count group_id="O6" value="816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="34.0"/>
                    <measurement group_id="O4" value="31.5"/>
                    <measurement group_id="O5" value="40.9"/>
                    <measurement group_id="O6" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="394"/>
                    <count group_id="O5" value="791"/>
                    <count group_id="O6" value="791"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="52.8"/>
                    <measurement group_id="O3" value="60.3"/>
                    <measurement group_id="O4" value="58.1"/>
                    <measurement group_id="O5" value="63.1"/>
                    <measurement group_id="O6" value="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="372"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="758"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="69.7"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="71.6"/>
                    <measurement group_id="O6" value="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="375"/>
                    <count group_id="O5" value="739"/>
                    <count group_id="O6" value="735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="66.9"/>
                    <measurement group_id="O3" value="73.8"/>
                    <measurement group_id="O4" value="74.1"/>
                    <measurement group_id="O5" value="76.6"/>
                    <measurement group_id="O6" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treaetment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="393"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="801"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="65.4"/>
                    <measurement group_id="O3" value="72.4"/>
                    <measurement group_id="O4" value="71.9"/>
                    <measurement group_id="O5" value="75.7"/>
                    <measurement group_id="O6" value="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants with a major (≥ 2 points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants with a major (≥ 2 points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="384"/>
                    <count group_id="O5" value="791"/>
                    <count group_id="O6" value="791"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="27.4"/>
                    <measurement group_id="O5" value="31.1"/>
                    <measurement group_id="O6" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="372"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="758"/>
                    <count group_id="O6" value="761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="35.0"/>
                    <measurement group_id="O4" value="40.5"/>
                    <measurement group_id="O5" value="42.7"/>
                    <measurement group_id="O6" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="375"/>
                    <count group_id="O5" value="739"/>
                    <count group_id="O6" value="735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="42.3"/>
                    <measurement group_id="O4" value="44.5"/>
                    <measurement group_id="O5" value="50.7"/>
                    <measurement group_id="O6" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="393"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="399"/>
                    <count group_id="O5" value="801"/>
                    <count group_id="O6" value="795"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="40.7"/>
                    <measurement group_id="O4" value="42.6"/>
                    <measurement group_id="O5" value="49.7"/>
                    <measurement group_id="O6" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="34.8"/>
                    <measurement group_id="O3" value="45.7"/>
                    <measurement group_id="O4" value="44.9"/>
                    <measurement group_id="O5" value="47.8"/>
                    <measurement group_id="O6" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="372"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="51.5"/>
                    <measurement group_id="O4" value="56.5"/>
                    <measurement group_id="O5" value="63.1"/>
                    <measurement group_id="O6" value="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="355"/>
                    <count group_id="O4" value="363"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="55.7"/>
                    <measurement group_id="O3" value="59.4"/>
                    <measurement group_id="O4" value="63.1"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="391"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="798"/>
                    <count group_id="O6" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="54.0"/>
                    <measurement group_id="O3" value="58.2"/>
                    <measurement group_id="O4" value="62.6"/>
                    <measurement group_id="O5" value="65.2"/>
                    <measurement group_id="O6" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.381</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="39.8"/>
                    <measurement group_id="O4" value="37.7"/>
                    <measurement group_id="O5" value="40.4"/>
                    <measurement group_id="O6" value="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="372"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="46.1"/>
                    <measurement group_id="O4" value="48.4"/>
                    <measurement group_id="O5" value="54.1"/>
                    <measurement group_id="O6" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="355"/>
                    <count group_id="O4" value="363"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="48.3"/>
                    <measurement group_id="O3" value="53.5"/>
                    <measurement group_id="O4" value="54.8"/>
                    <measurement group_id="O5" value="61.6"/>
                    <measurement group_id="O6" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="391"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="798"/>
                    <count group_id="O6" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="46.0"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="54.0"/>
                    <measurement group_id="O5" value="59.0"/>
                    <measurement group_id="O6" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="785"/>
                    <count group_id="O6" value="780"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="37.7"/>
                    <measurement group_id="O4" value="34.5"/>
                    <measurement group_id="O5" value="39.9"/>
                    <measurement group_id="O6" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="367"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="372"/>
                    <count group_id="O5" value="751"/>
                    <count group_id="O6" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="44.7"/>
                    <measurement group_id="O3" value="50.1"/>
                    <measurement group_id="O4" value="51.3"/>
                    <measurement group_id="O5" value="53.8"/>
                    <measurement group_id="O6" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="355"/>
                    <count group_id="O4" value="364"/>
                    <count group_id="O5" value="728"/>
                    <count group_id="O6" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="51.7"/>
                    <measurement group_id="O3" value="54.9"/>
                    <measurement group_id="O4" value="56.9"/>
                    <measurement group_id="O5" value="62.0"/>
                    <measurement group_id="O6" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="799"/>
                    <count group_id="O6" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="48.5"/>
                    <measurement group_id="O3" value="53.9"/>
                    <measurement group_id="O4" value="56.0"/>
                    <measurement group_id="O5" value="59.9"/>
                    <measurement group_id="O6" value="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of lncontinence episodes per 24 hours and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of lncontinence episodes per 24 hours and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of lncontinence episodes per 24 hours and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of lncontinence episodes per 24 hours and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="33.6"/>
                    <measurement group_id="O4" value="31.4"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="372"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="47.8"/>
                    <measurement group_id="O5" value="51.6"/>
                    <measurement group_id="O6" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="355"/>
                    <count group_id="O4" value="363"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="49.6"/>
                    <measurement group_id="O4" value="54.5"/>
                    <measurement group_id="O5" value="58.2"/>
                    <measurement group_id="O6" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="391"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="798"/>
                    <count group_id="O6" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="48.4"/>
                    <measurement group_id="O4" value="53.3"/>
                    <measurement group_id="O5" value="56.3"/>
                    <measurement group_id="O6" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.335</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
        <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the HRQL total score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
        <time_frame>Weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT</title>
          <description>The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the HRQL total score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</description>
          <population>FAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="415"/>
                <count group_id="O5" value="827"/>
                <count group_id="O6" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="784"/>
                    <count group_id="O6" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="30.0"/>
                    <measurement group_id="O4" value="28.6"/>
                    <measurement group_id="O5" value="32.7"/>
                    <measurement group_id="O6" value="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="372"/>
                    <count group_id="O5" value="750"/>
                    <count group_id="O6" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="43.0"/>
                    <measurement group_id="O5" value="46.3"/>
                    <measurement group_id="O6" value="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="355"/>
                    <count group_id="O4" value="363"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="45.6"/>
                    <measurement group_id="O4" value="49.9"/>
                    <measurement group_id="O5" value="54.5"/>
                    <measurement group_id="O6" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="391"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="798"/>
                    <count group_id="O6" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="39.1"/>
                    <measurement group_id="O3" value="44.8"/>
                    <measurement group_id="O4" value="49.2"/>
                    <measurement group_id="O5" value="51.6"/>
                    <measurement group_id="O6" value="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.416</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Odds ratio from a logistic regression model including treatment group, sex, age group (&lt;65, &gt;=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>A TEAE refered to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing.</description>
        <time_frame>From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)</time_frame>
        <population>Safety Analysis Set (SAF), which comprised all randomized participants who received ≥ 1 dose of double-blind treatment and excluded participants from one site.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>A TEAE refered to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing.</description>
          <population>Safety Analysis Set (SAF), which comprised all randomized participants who received ≥ 1 dose of double-blind treatment and excluded participants from one site.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="422"/>
                <count group_id="O4" value="423"/>
                <count group_id="O5" value="853"/>
                <count group_id="O6" value="848"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="149"/>
                    <measurement group_id="O5" value="345"/>
                    <measurement group_id="O6" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="157"/>
                    <measurement group_id="O6" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume</title>
        <description>PVR volume was assessed by ultrasonography or a bladder scanner.</description>
        <time_frame>Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)</time_frame>
        <population>SAF participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume</title>
          <description>PVR volume was assessed by ultrasonography or a bladder scanner.</description>
          <population>SAF participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="423"/>
                <count group_id="O3" value="422"/>
                <count group_id="O4" value="423"/>
                <count group_id="O5" value="853"/>
                <count group_id="O6" value="848"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="397"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="815"/>
                    <count group_id="O6" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="29.9"/>
                    <measurement group_id="O2" value="1.6" spread="28.0"/>
                    <measurement group_id="O3" value="-2.1" spread="29.7"/>
                    <measurement group_id="O4" value="5.8" spread="35.6"/>
                    <measurement group_id="O5" value="7.2" spread="47.7"/>
                    <measurement group_id="O6" value="10.6" spread="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="383"/>
                    <count group_id="O4" value="393"/>
                    <count group_id="O5" value="779"/>
                    <count group_id="O6" value="784"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="28.6"/>
                    <measurement group_id="O2" value="-0.4" spread="29.8"/>
                    <measurement group_id="O3" value="-0.6" spread="34.4"/>
                    <measurement group_id="O4" value="5.4" spread="35.2"/>
                    <measurement group_id="O5" value="7.0" spread="37.4"/>
                    <measurement group_id="O6" value="9.9" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="376"/>
                    <count group_id="O3" value="370"/>
                    <count group_id="O4" value="383"/>
                    <count group_id="O5" value="766"/>
                    <count group_id="O6" value="763"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="29.9"/>
                    <measurement group_id="O2" value="1.0" spread="29.8"/>
                    <measurement group_id="O3" value="0.0" spread="30.1"/>
                    <measurement group_id="O4" value="4.7" spread="33.1"/>
                    <measurement group_id="O5" value="7.9" spread="44.4"/>
                    <measurement group_id="O6" value="9.6" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="410"/>
                    <count group_id="O2" value="401"/>
                    <count group_id="O3" value="404"/>
                    <count group_id="O4" value="414"/>
                    <count group_id="O5" value="821"/>
                    <count group_id="O6" value="815"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="29.4"/>
                    <measurement group_id="O2" value="0.7" spread="29.1"/>
                    <measurement group_id="O3" value="-0.8" spread="30.0"/>
                    <measurement group_id="O4" value="4.8" spread="33.3"/>
                    <measurement group_id="O5" value="9.0" spread="55.0"/>
                    <measurement group_id="O6" value="11.0" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPM analysis set (ABPMAS), which consisted of all participants in the SAF for whom at least 1 ABPM variable could be calculated at baseline and postbaseline visit. Participants with data available at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
          <population>ABPM analysis set (ABPMAS), which consisted of all participants in the SAF for whom at least 1 ABPM variable could be calculated at baseline and postbaseline visit. Participants with data available at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="1.22"/>
                    <measurement group_id="O2" value="-2.04" spread="1.31"/>
                    <measurement group_id="O3" value="0.96" spread="1.30"/>
                    <measurement group_id="O4" value="1.03" spread="1.26"/>
                    <measurement group_id="O5" value="-0.85" spread="0.90"/>
                    <measurement group_id="O6" value="0.31" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.22"/>
                    <measurement group_id="O2" value="-1.19" spread="1.33"/>
                    <measurement group_id="O3" value="-0.67" spread="1.31"/>
                    <measurement group_id="O4" value="-1.13" spread="1.34"/>
                    <measurement group_id="O5" value="-1.63" spread="0.91"/>
                    <measurement group_id="O6" value="-0.53" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="147"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="1.38"/>
                    <measurement group_id="O2" value="-1.14" spread="1.46"/>
                    <measurement group_id="O3" value="1.42" spread="1.44"/>
                    <measurement group_id="O4" value="0.41" spread="1.47"/>
                    <measurement group_id="O5" value="1.14" spread="1.03"/>
                    <measurement group_id="O6" value="0.54" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.37"/>
                    <measurement group_id="O2" value="-2.70" spread="1.42"/>
                    <measurement group_id="O3" value="-1.75" spread="1.41"/>
                    <measurement group_id="O4" value="0.40" spread="1.45"/>
                    <measurement group_id="O5" value="-0.71" spread="1.02"/>
                    <measurement group_id="O6" value="0.40" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="106"/>
                    <count group_id="O6" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="1.37"/>
                    <measurement group_id="O2" value="-2.53" spread="1.46"/>
                    <measurement group_id="O3" value="-2.14" spread="1.48"/>
                    <measurement group_id="O4" value="-2.09" spread="1.50"/>
                    <measurement group_id="O5" value="-0.39" spread="1.06"/>
                    <measurement group_id="O6" value="-0.71" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="1.64"/>
                    <measurement group_id="O2" value="-2.81" spread="1.77"/>
                    <measurement group_id="O3" value="-0.77" spread="1.68"/>
                    <measurement group_id="O4" value="1.31" spread="1.76"/>
                    <measurement group_id="O5" value="0.11" spread="1.23"/>
                    <measurement group_id="O6" value="0.79" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="1.24"/>
                    <measurement group_id="O2" value="-3.44" spread="1.29"/>
                    <measurement group_id="O3" value="-1.14" spread="1.27"/>
                    <measurement group_id="O4" value="0.37" spread="1.25"/>
                    <measurement group_id="O5" value="-0.52" spread="0.90"/>
                    <measurement group_id="O6" value="-0.08" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.22"/>
                    <measurement group_id="O2" value="-3.29" spread="1.31"/>
                    <measurement group_id="O3" value="-1.92" spread="1.30"/>
                    <measurement group_id="O4" value="-2.17" spread="1.30"/>
                    <measurement group_id="O5" value="-0.68" spread="0.92"/>
                    <measurement group_id="O6" value="-1.28" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="1.47"/>
                    <measurement group_id="O2" value="-3.48" spread="1.54"/>
                    <measurement group_id="O3" value="-0.60" spread="1.52"/>
                    <measurement group_id="O4" value="1.42" spread="1.52"/>
                    <measurement group_id="O5" value="0.41" spread="1.09"/>
                    <measurement group_id="O6" value="0.91" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.50"/>
                    <measurement group_id="O2" value="-0.86" spread="0.54"/>
                    <measurement group_id="O3" value="0.22" spread="0.54"/>
                    <measurement group_id="O4" value="0.25" spread="0.52"/>
                    <measurement group_id="O5" value="0.03" spread="0.37"/>
                    <measurement group_id="O6" value="0.38" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.53"/>
                    <measurement group_id="O2" value="-0.36" spread="0.58"/>
                    <measurement group_id="O3" value="-0.33" spread="0.57"/>
                    <measurement group_id="O4" value="-0.77" spread="0.58"/>
                    <measurement group_id="O5" value="-0.40" spread="0.40"/>
                    <measurement group_id="O6" value="0.07" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="147"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.59"/>
                    <measurement group_id="O2" value="-0.97" spread="0.62"/>
                    <measurement group_id="O3" value="0.40" spread="0.62"/>
                    <measurement group_id="O4" value="0.48" spread="0.63"/>
                    <measurement group_id="O5" value="0.93" spread="0.44"/>
                    <measurement group_id="O6" value="0.47" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.56"/>
                    <measurement group_id="O2" value="-0.93" spread="0.58"/>
                    <measurement group_id="O3" value="-0.19" spread="0.57"/>
                    <measurement group_id="O4" value="0.43" spread="0.59"/>
                    <measurement group_id="O5" value="-0.37" spread="0.41"/>
                    <measurement group_id="O6" value="0.31" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="106"/>
                    <count group_id="O6" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.60"/>
                    <measurement group_id="O2" value="-0.54" spread="0.64"/>
                    <measurement group_id="O3" value="-0.40" spread="0.65"/>
                    <measurement group_id="O4" value="-0.33" spread="0.66"/>
                    <measurement group_id="O5" value="-0.06" spread="0.46"/>
                    <measurement group_id="O6" value="-0.18" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.66"/>
                    <measurement group_id="O2" value="-1.39" spread="0.71"/>
                    <measurement group_id="O3" value="-0.03" spread="0.68"/>
                    <measurement group_id="O4" value="0.92" spread="0.71"/>
                    <measurement group_id="O5" value="0.23" spread="0.49"/>
                    <measurement group_id="O6" value="0.49" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.51"/>
                    <measurement group_id="O2" value="-1.41" spread="0.53"/>
                    <measurement group_id="O3" value="-0.11" spread="0.52"/>
                    <measurement group_id="O4" value="0.05" spread="0.52"/>
                    <measurement group_id="O5" value="-0.02" spread="0.37"/>
                    <measurement group_id="O6" value="0.25" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.53"/>
                    <measurement group_id="O2" value="-0.98" spread="0.58"/>
                    <measurement group_id="O3" value="-0.69" spread="0.57"/>
                    <measurement group_id="O4" value="-0.79" spread="0.57"/>
                    <measurement group_id="O5" value="-0.18" spread="0.40"/>
                    <measurement group_id="O6" value="-0.36" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.60"/>
                    <measurement group_id="O2" value="-2.00" spread="0.63"/>
                    <measurement group_id="O3" value="0.08" spread="0.63"/>
                    <measurement group_id="O4" value="0.71" spread="0.63"/>
                    <measurement group_id="O5" value="0.56" spread="0.45"/>
                    <measurement group_id="O6" value="0.61" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.63"/>
                    <measurement group_id="O2" value="1.14" spread="0.68"/>
                    <measurement group_id="O3" value="2.32" spread="0.67"/>
                    <measurement group_id="O4" value="0.36" spread="0.65"/>
                    <measurement group_id="O5" value="0.40" spread="0.46"/>
                    <measurement group_id="O6" value="0.69" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.73"/>
                    <measurement group_id="O2" value="1.19" spread="0.79"/>
                    <measurement group_id="O3" value="3.52" spread="0.78"/>
                    <measurement group_id="O4" value="0.37" spread="0.80"/>
                    <measurement group_id="O5" value="-0.05" spread="0.54"/>
                    <measurement group_id="O6" value="0.61" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="147"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.68"/>
                    <measurement group_id="O2" value="0.98" spread="0.71"/>
                    <measurement group_id="O3" value="1.77" spread="0.70"/>
                    <measurement group_id="O4" value="1.09" spread="0.72"/>
                    <measurement group_id="O5" value="0.86" spread="0.50"/>
                    <measurement group_id="O6" value="0.86" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.72"/>
                    <measurement group_id="O2" value="0.38" spread="0.74"/>
                    <measurement group_id="O3" value="1.19" spread="0.74"/>
                    <measurement group_id="O4" value="0.12" spread="0.76"/>
                    <measurement group_id="O5" value="0.94" spread="0.53"/>
                    <measurement group_id="O6" value="1.44" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="106"/>
                    <count group_id="O6" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.82"/>
                    <measurement group_id="O2" value="0.25" spread="0.88"/>
                    <measurement group_id="O3" value="2.12" spread="0.89"/>
                    <measurement group_id="O4" value="-0.13" spread="0.90"/>
                    <measurement group_id="O5" value="0.84" spread="0.64"/>
                    <measurement group_id="O6" value="1.36" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.71"/>
                    <measurement group_id="O2" value="0.21" spread="0.77"/>
                    <measurement group_id="O3" value="0.19" spread="0.73"/>
                    <measurement group_id="O4" value="0.06" spread="0.76"/>
                    <measurement group_id="O5" value="0.76" spread="0.53"/>
                    <measurement group_id="O6" value="1.52" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: 24-hour mean</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.65"/>
                    <measurement group_id="O2" value="0.63" spread="0.68"/>
                    <measurement group_id="O3" value="1.67" spread="0.67"/>
                    <measurement group_id="O4" value="0.02" spread="0.66"/>
                    <measurement group_id="O5" value="0.85" spread="0.47"/>
                    <measurement group_id="O6" value="1.52" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean daytime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.74"/>
                    <measurement group_id="O2" value="0.37" spread="0.80"/>
                    <measurement group_id="O3" value="2.64" spread="0.79"/>
                    <measurement group_id="O4" value="-0.07" spread="0.79"/>
                    <measurement group_id="O5" value="0.32" spread="0.56"/>
                    <measurement group_id="O6" value="1.24" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment: mean nighttime</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.66"/>
                    <measurement group_id="O2" value="0.82" spread="0.69"/>
                    <measurement group_id="O3" value="0.75" spread="0.68"/>
                    <measurement group_id="O4" value="0.45" spread="0.68"/>
                    <measurement group_id="O5" value="1.21" spread="0.49"/>
                    <measurement group_id="O6" value="1.64" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="1.68"/>
                    <measurement group_id="O2" value="0.34" spread="1.86"/>
                    <measurement group_id="O3" value="-1.03" spread="1.72"/>
                    <measurement group_id="O4" value="-1.77" spread="1.74"/>
                    <measurement group_id="O5" value="-1.55" spread="1.23"/>
                    <measurement group_id="O6" value="-1.47" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.86" spread="1.78"/>
                    <measurement group_id="O2" value="-2.13" spread="1.95"/>
                    <measurement group_id="O3" value="-1.64" spread="1.88"/>
                    <measurement group_id="O4" value="-3.15" spread="1.96"/>
                    <measurement group_id="O5" value="-0.26" spread="1.32"/>
                    <measurement group_id="O6" value="0.60" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="157"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.40" spread="1.60"/>
                    <measurement group_id="O2" value="-2.19" spread="1.68"/>
                    <measurement group_id="O3" value="-1.94" spread="1.64"/>
                    <measurement group_id="O4" value="-3.64" spread="1.65"/>
                    <measurement group_id="O5" value="-0.61" spread="1.16"/>
                    <measurement group_id="O6" value="-0.98" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.84"/>
                    <measurement group_id="O2" value="0.09" spread="0.93"/>
                    <measurement group_id="O3" value="-0.65" spread="0.86"/>
                    <measurement group_id="O4" value="-0.48" spread="0.87"/>
                    <measurement group_id="O5" value="-0.22" spread="0.62"/>
                    <measurement group_id="O6" value="-0.71" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="0.92"/>
                    <measurement group_id="O2" value="-0.45" spread="1.00"/>
                    <measurement group_id="O3" value="-0.31" spread="0.97"/>
                    <measurement group_id="O4" value="-1.49" spread="1.01"/>
                    <measurement group_id="O5" value="0.48" spread="0.68"/>
                    <measurement group_id="O6" value="-0.03" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="157"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.84"/>
                    <measurement group_id="O2" value="-0.71" spread="0.88"/>
                    <measurement group_id="O3" value="-0.71" spread="0.85"/>
                    <measurement group_id="O4" value="-1.22" spread="0.86"/>
                    <measurement group_id="O5" value="0.44" spread="0.61"/>
                    <measurement group_id="O6" value="-0.80" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.08"/>
                    <measurement group_id="O2" value="2.39" spread="1.19"/>
                    <measurement group_id="O3" value="3.68" spread="1.10"/>
                    <measurement group_id="O4" value="0.47" spread="1.11"/>
                    <measurement group_id="O5" value="-0.91" spread="0.79"/>
                    <measurement group_id="O6" value="0.67" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="1.10"/>
                    <measurement group_id="O2" value="1.22" spread="1.20"/>
                    <measurement group_id="O3" value="1.87" spread="1.16"/>
                    <measurement group_id="O4" value="0.37" spread="1.21"/>
                    <measurement group_id="O5" value="0.15" spread="0.81"/>
                    <measurement group_id="O6" value="1.39" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="157"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.05"/>
                    <measurement group_id="O2" value="0.82" spread="1.10"/>
                    <measurement group_id="O3" value="3.41" spread="1.07"/>
                    <measurement group_id="O4" value="-1.25" spread="1.08"/>
                    <measurement group_id="O5" value="0.34" spread="0.76"/>
                    <measurement group_id="O6" value="1.25" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.05" spread="2.06"/>
                    <measurement group_id="O2" value="31.14" spread="2.20"/>
                    <measurement group_id="O3" value="38.20" spread="2.19"/>
                    <measurement group_id="O4" value="35.16" spread="2.11"/>
                    <measurement group_id="O5" value="32.88" spread="1.51"/>
                    <measurement group_id="O6" value="32.80" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.21" spread="2.30"/>
                    <measurement group_id="O2" value="30.68" spread="2.38"/>
                    <measurement group_id="O3" value="32.88" spread="2.36"/>
                    <measurement group_id="O4" value="35.11" spread="2.42"/>
                    <measurement group_id="O5" value="33.53" spread="1.70"/>
                    <measurement group_id="O6" value="32.82" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.98" spread="2.11"/>
                    <measurement group_id="O2" value="30.65" spread="2.20"/>
                    <measurement group_id="O3" value="33.53" spread="2.16"/>
                    <measurement group_id="O4" value="34.95" spread="2.14"/>
                    <measurement group_id="O5" value="34.70" spread="1.54"/>
                    <measurement group_id="O6" value="32.55" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.78" spread="1.27"/>
                    <measurement group_id="O2" value="19.15" spread="1.36"/>
                    <measurement group_id="O3" value="20.41" spread="1.35"/>
                    <measurement group_id="O4" value="20.02" spread="1.31"/>
                    <measurement group_id="O5" value="20.74" spread="0.93"/>
                    <measurement group_id="O6" value="20.27" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.68" spread="1.23"/>
                    <measurement group_id="O2" value="19.52" spread="1.28"/>
                    <measurement group_id="O3" value="20.41" spread="1.27"/>
                    <measurement group_id="O4" value="21.18" spread="1.30"/>
                    <measurement group_id="O5" value="19.26" spread="0.92"/>
                    <measurement group_id="O6" value="20.01" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.29" spread="1.16"/>
                    <measurement group_id="O2" value="19.29" spread="1.22"/>
                    <measurement group_id="O3" value="20.71" spread="1.19"/>
                    <measurement group_id="O4" value="20.47" spread="1.18"/>
                    <measurement group_id="O5" value="20.29" spread="0.85"/>
                    <measurement group_id="O6" value="20.36" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline ≥ 0 mmHg) were included in the analysis. LOCF was used for EoT.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.34" spread="1.35"/>
                    <measurement group_id="O2" value="23.86" spread="1.44"/>
                    <measurement group_id="O3" value="25.12" spread="1.43"/>
                    <measurement group_id="O4" value="24.28" spread="1.38"/>
                    <measurement group_id="O5" value="21.48" spread="0.99"/>
                    <measurement group_id="O6" value="21.80" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.63" spread="1.42"/>
                    <measurement group_id="O2" value="23.54" spread="1.47"/>
                    <measurement group_id="O3" value="26.03" spread="1.46"/>
                    <measurement group_id="O4" value="23.52" spread="1.50"/>
                    <measurement group_id="O5" value="22.60" spread="1.05"/>
                    <measurement group_id="O6" value="24.08" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.01" spread="1.31"/>
                    <measurement group_id="O2" value="24.12" spread="1.37"/>
                    <measurement group_id="O3" value="26.23" spread="1.34"/>
                    <measurement group_id="O4" value="23.33" spread="1.33"/>
                    <measurement group_id="O5" value="22.66" spread="0.96"/>
                    <measurement group_id="O6" value="24.14" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="1.86"/>
                    <measurement group_id="O2" value="0.14" spread="1.99"/>
                    <measurement group_id="O3" value="-0.69" spread="1.98"/>
                    <measurement group_id="O4" value="0.85" spread="1.91"/>
                    <measurement group_id="O5" value="-1.61" spread="1.36"/>
                    <measurement group_id="O6" value="0.41" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="1.98"/>
                    <measurement group_id="O2" value="-2.45" spread="2.05"/>
                    <measurement group_id="O3" value="-4.55" spread="2.03"/>
                    <measurement group_id="O4" value="-1.63" spread="2.08"/>
                    <measurement group_id="O5" value="0.68" spread="1.47"/>
                    <measurement group_id="O6" value="0.62" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.83"/>
                    <measurement group_id="O2" value="-1.38" spread="1.91"/>
                    <measurement group_id="O3" value="-2.30" spread="1.87"/>
                    <measurement group_id="O4" value="-0.97" spread="1.85"/>
                    <measurement group_id="O5" value="0.25" spread="1.33"/>
                    <measurement group_id="O6" value="0.68" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>nnHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="1.31"/>
                    <measurement group_id="O2" value="-1.08" spread="1.40"/>
                    <measurement group_id="O3" value="-0.20" spread="1.39"/>
                    <measurement group_id="O4" value="-1.60" spread="1.34"/>
                    <measurement group_id="O5" value="0.39" spread="0.96"/>
                    <measurement group_id="O6" value="-0.56" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.30"/>
                    <measurement group_id="O2" value="0.15" spread="1.34"/>
                    <measurement group_id="O3" value="-1.90" spread="1.33"/>
                    <measurement group_id="O4" value="-0.66" spread="1.36"/>
                    <measurement group_id="O5" value="-1.24" spread="0.96"/>
                    <measurement group_id="O6" value="0.46" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="1.23"/>
                    <measurement group_id="O2" value="0.27" spread="1.28"/>
                    <measurement group_id="O3" value="-0.96" spread="1.26"/>
                    <measurement group_id="O4" value="-1.67" spread="1.24"/>
                    <measurement group_id="O5" value="-0.98" spread="0.89"/>
                    <measurement group_id="O6" value="0.52" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference</title>
        <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
        <time_frame>Baseline and weeks 4, 12 and EoT (up to 12 weeks)</time_frame>
        <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received matching placebo once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron 25 mg</title>
            <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron 50 mg</title>
            <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Solifenacin 5 mg</title>
            <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
            <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference</title>
          <description>Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</description>
          <population>ABPMAS participants with available data at each time point were included in the analysis. LOCF was used for EoT.</population>
          <units>bpm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.38"/>
                    <measurement group_id="O2" value="0.46" spread="1.48"/>
                    <measurement group_id="O3" value="1.54" spread="1.46"/>
                    <measurement group_id="O4" value="0.78" spread="1.41"/>
                    <measurement group_id="O5" value="-0.68" spread="1.01"/>
                    <measurement group_id="O6" value="-0.51" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="1.45"/>
                    <measurement group_id="O2" value="-0.04" spread="1.50"/>
                    <measurement group_id="O3" value="1.15" spread="1.49"/>
                    <measurement group_id="O4" value="3.49" spread="1.53"/>
                    <measurement group_id="O5" value="-0.53" spread="1.07"/>
                    <measurement group_id="O6" value="1.48" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="1.32"/>
                    <measurement group_id="O2" value="0.45" spread="1.37"/>
                    <measurement group_id="O3" value="1.14" spread="1.35"/>
                    <measurement group_id="O4" value="3.16" spread="1.33"/>
                    <measurement group_id="O5" value="-0.02" spread="0.96"/>
                    <measurement group_id="O6" value="1.80" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants who received matching placebo once a day for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Mirabegron 25 mg</title>
          <description>Participants who received mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Mirabegron 50 mg</title>
          <description>Participants who received mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Solifenacin 5 mg</title>
          <description>Participants who received solifenacin 5 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Solifenacin 5 mg + Mirabegron 25 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Solifenacin 5 mg + Mirabegron 50 mg</title>
          <description>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal stone removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="848"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="423"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="423"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="853"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="848"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication temporarily to seek patent protection or permanently withhold the publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to lack of data integrity, one site’s data was not included in the efficacy and safety analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Astellas Pharma Europe B.V.</organization>
      <phone>+31 (0) 71 5455 050</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

